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1 Contrast Enhanced Ultrasound
1.1 Introduction to ultrasound
Observation on bats led the Italian priest Spallanzani to the idea of animal echoloca-
tion based on inaudible sound. In the late 19th century, experiments with Galton’s
whistle on animals led to refinements of the understanding of sound waves that are
just beyond the human perception but are audible for smaller mammals. Audible
mechanical waves, or ”acoustic” waves that humans can sense, have a frequency be-
tween 20 Hz - 20 kHz. Sound waves with a lower frequency than 20 Hz are termed
infra sound while waves with higher frequency than 20 kHz are termed ultrasound.
Regardless of their frequency, they propagate by longitudinal motion via compres-
sion and rarefaction of matter.
Today, ultrasound is routinely applied worldwide in various imaging protocols,
material assessment and other industrial applications or even in the consumer sector
as home therapy devices or for cleaning purposes.
Anecdotal, the development of ultrasound for various applications is based on two
events unfolding around the turn of the 19th century.
The first was the experimental demonstration of the piezoelectric effect in 1880
by the two Curie brothers Jacques and Pierre, which constitutes the core principle
of the generation and detection of ultrasound.
The second was the tragic disaster of the RMS Titanic in 1912, which fueled pub-
lic - and most importantly military - interests to detect non-visible and submerged
obstacles, ranging from icebergs and riffs to hostile submarines. Great efforts and
the incorporation of various technological advances led to the development of sound-
based echolocation and echography.
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Piezoelectricity describes a process where applied mechanical force on a crystal
lattice causes change in the local polarization density which subsequently results in
the generation of a differential electric charge (see figure 1.1). This effect is called
the direct piezoelectric effect and the generated electric charge is proportional to the
degree of deformation exercised on the material, which can be for example quartz,
barium titanate or lead zirconate. The crystals’ thickness determines the resonance
frequency, where output would be maximal.
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Figure 1.1: Schematics of the direct and reversed piezo-effect. A current forces the crystal
material to change shape and thus converts electric into mechanical energy. Applied stress
on the resting crystal transforms mechanical into electric energy that can be used to detect
the returning ultrasound waves.
But most importantly, this effect can be reversed. In the reversed piezoelectric
effect, an applied voltage forces the crystal to expand or shrink and acts as a ”motor”.
This principle is exploited for the formation of ultrasound waves by applying an
alternating current.
Figure 1.2: Schematic of
an ultrasound imaging trans-
ducer.
The single-phase current is inverted at a distinct fre-
quency to force the crystal material into a stable os-
cillatory deformation that results in the generation of
a pressure wave, which propagates through the tissue
via compression and rarefaction as a longitudinal wave.
The piezoelectric crystals in the transducer are only
briefly forced to actively generate ultrasound waves and
will return to a passive state to detect back scattered
waves (”echoes”) and the established voltages caused
by the direct piezo effect are measured and analyzed.
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The composition of an ultrasound transducer is complex, but the underlying princi-
ple is a piezoelectric crystal between opposing electrodes and an individual enclosure
with an acoustic insulator (see figure 1.2). A dampening material ensures a steeper
up- and down-ramping of the crystal oscillations and ensures a unidirectional emis-
sion of sound waves. Multiple piezoelectric elements are combined into an array and
by selective and time-phased activation, complex waves can be generated.
1.2 Properties of ultrasound waves
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Figure 1.3: Propagation
of a pulsed sound wave.
Ultrasound pulses produced by the oscillatory crystal de-
formation will travel through the tissue as a pressure
wave (see figure 1.3) The tissue undergoes cyclic pres-
sure variations (compression and rarefaction) parallel to
the longitudinal wave’s propagation path. Local differ-
ences in acoustic impedance caused by solid objects or
tissue interfaces (e.g. lumen vs. vessel wall, muscle vs.
bone) will reflect the incident sound waves back to the
transmitter (t3 in figure 1.3), where it will be registered.
The temporal difference between the emission and recep-
tion of a sound wave is due to the traveled path, which
has to be twice the distance between transducer and ob-
ject.
With knowledge of the propagation velocity, the depth of a signal reflection can be
reconstructed. Because an emitted ultrasound pulse will travel through tissue with
varying density, it will on its path produce a multitude of returning echoes. The de-
tected voltages at the transducer will be amplified, filtered and processed (including
demodulation, envelop detection, log compression etc.) and powerful computational
capacity is needed to construct a real-time image.
An ultrasound wave is characterized by its sinusoidal frequency that falls between
2 MHz - 10 MHz for clinical ultrasound, but can even be used above 40 MHz for
high-resolution imaging.
Pressure waves can be thought of as continuous sinus waves characterized by wave
length λ and amplitude.
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Figure 1.4: Pressure waves are characterized by amplitude and wave length λ. The
pressure wave induces local compressions (C) and rarefactions (R) and propagates through
matter with a certain velocity (air: 330 m/s, soft body tissue 1500 m/s and more than
4000 m/s for solids like bone).
The wavelength λ is the spatial dimension between two points with the same phase
(from peak pressure nadir to peak pressure nadir) and depends on the propagation
speed (c) and inversely on the frequency of compressions/rarefactions per second
(f)
Wavelength λ =
c
f
. (1.1)
Medical ultrasound with fundamental frequencies between 2 - 15 MHz typically has
a wave length of 0.8 - 0.1 mm in tissue. The propagation speed is dependent on the
matter that it travels through and averages 1’540 m/s for soft tissue. More exactly,
the propagation speed c of a pressure wave depends on the tissue density ρ and
compressibility κ and follows the equation
Propagation speed c =
√
1
κρ
. (1.2)
In soft tissue, ultrasound waves travel with 1’450 m/s (fat) - 1’580 m/s (muscle),
while in hard tissue like bone the velocity exceeds 4’000 m/s.
The second parameter of a wave is it’s amplitude. For ultrasound waves, ampli-
tude is equal with the degree of tissue displacement transmitted as pressure. The
maximal allowed value in diagnostic ultrasound is 4 MPa for peak negative acoustic
pressure. The intensity I of an ultrasound wave is dependent on pressure P squared,
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the tissue density ρ and the specific propagation speed c.
Intensity I =
P 2
ρ× c (1.3)
When tissue density and propagation speed are assumed to be constant, the intensity
of a soundwave is proportional to pressure squared.
Intensity I ∝ P 2 (1.4)
Manufacturers of ultrasound equipment are obliged to display real-time mechani-
cal and thermal indices on the user interfaces as a metrical indicator to rate possible
effects on the examined tissue. The mechanical index (MI) is an estimate of tissue
damage by cavitation effects that happens at high pressure differentials. For diagnos-
tic ultrasound, a value below 0.3 is accepted to not have any effect and the maximal
allowed value for MI is 1.9. The mechanical index is a measure of peak negative pres-
sure (Pneg) during a rarefaction divided by the square root of the center frequency
fc. It is determined for a ultrasound system in water where an attenuation-corrected
peak negative pressure αPr depending on penetration depth zMI is measured with a
hydrophone in respect to attenuation-corrected center frequency (
√
fc(cMI)) at one
focus point.
Mechanical index (MI) =
αPneg(zMI)√
fc(cMI)
. (1.5)
In diagnostic ultrasound exams with a 2.5 MHz transducer and a MI=1.3, these
settings would result in peak negative pressures of 2 MPa and thus a total pressure
differential of 4 MPa in a timespan of 0.2 μs. This is equivalent to a pressure change
from 400 m below sea level to the surface in 1/5′000′000th of a second.
1.3 Attenuation of ultrasound waves
However complex, the average intensity of an ultrasound beam that passes through
an area of tissue can be expressed as
average Intensity I =
power [mW]
area [cm2]
. (1.6)
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The cross section of an ultrasound beam will diverge with increasing penetration
depth and the intensity is proportional to distance r squared. It should be noted
that the maximal intensity is highest at the center of the beam and falls off towards
the periphery.
Intensity I ∝ 1
r2
. (1.7)
The loss in intensity (thus amplitude) of a wave over distance is called attenuation.
It relies on interaction of pressure waves with the penetrated tissue that include
reflection, scattering and absorption.
When a pressure wave arrives at a tissue interface of different acoustic impedance,
it will be reflected as a specular or mirrored wave at a complementary angle θreflected
to the incident angle θincident. Most of the signal detected in ultrasound imaging
are specular reflections that have an incident angle θincident close to 90
◦ at smooth
boundaries.
Diffuse
reflection
Specular
reflection
low impedance
high impedance
Objects < λ
Heat
Figure 1.5: Representation of a continuous incident sound-wave that hits a tissue interface
at 90◦ and is subsequently reflected back to the transducer where it can be detected. In
case of irregularities at the interface, the wave can be reflected diffusely at various angles.
Part of the wave’s energy will pass through the interface where it gets refracted during the
transition. If the wave hits objects smaller than its λ, it will be scattered. The mechanical
energy of the wave is also transformed into heat and thus intensity absorbed in the tissue.
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However, due to the non-homogeneous character of biological interfaces that con-
tain irregularities in various sizes, part of the incident waves will be reflected dif-
fusely, especially when the irregular structures have similar dimensions as the in-
cident wave length. Diffuse reflections contribute to the decrease of a ultrasound
waves’ intensity over a traveled distance, but a large part of the reflected energy
travels back to the transducer where it is detected. Structures much smaller than
the wavelength, e.g. red blood cells that have a diameter of 7 μm vs. a typical
ultrasound wavelength of λ= 500 μm will scatter the incoming sound wave in ev-
ery direction (Reyleigh scattering) and only a small amount of the scattered sound
waves will be detected at the transducer. The stochastic backscatter of diffuse re-
flections and most importantly the Reyleigh scattering at small structures are low in
energy, but will give the tissue a characteristic texture or signature in 2-dimensional
ultrasound images and allows computational intense tracking of these patterns.
In contrast to scattering and reflections, absorption is a gradual process that is
mostly dependent on distance traveled, and the energy of a sound wave is converted
from vibration into heat. The attenuation is expressed in decibels depending on the
ratio between propagated and received intensity:
Attenuation (dB) = 10× log10
(
received intensity
propagated intensity
)
(1.8)
Table 1.1: Attenuation in dB
to the ratio of received signalpropagated signal
dB ratio
0 1:1
-3 1:2
-7 1:5
-10 1:10
-20 1:100
-30 1:1’000
... ...
In soft tissue, the attenuation coefficient α is around
1 dB cm−1 MHz−1, which would translate into a de-
crease in signal intensity of 21% per cm and MHz. At
an exemplary imaging depth of 1.5 cm, the received
intensity of a 1 MHz wave would theoretically be only
half of the propagated intensity (see table 1.1). The
signals thus need to be amplified in accordance to their
travel time in a step called time-gain compensation.
For skeletal muscle, the average attenuation is greater
than 1.5 dB cm−1 MHz−1 and differs profoundly when
imaging is performed either longitudinal or orthogonal in respect to its muscle fibers.
Lung tissue attenuates ultrasound waves even at a higher magnitude than air or bone
(see figure 1.14) due to the small air-filled pockets formed by alveoli, which help re-
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fracting the incident wave effectively. Ultrasound waves with higher frequencies will
be attenuated over a shorter distance and thus will penetrate tissue to a lesser depth
than lower frequency waves as it is shown for e.g. 3.5 MHz, 7 MHz and 15 MHz in
muscle in figure 1.14.
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Figure 1.6: Theoretical attenuation for imaging with 7 MHz in respect to traveled dis-
tance for selected tissues. Blood does show the smallest attenuation in contrast to bone
and lung. For muscle, three different frequencies are shown. Waves with a higher frequency
show a faster attenuation over travel distance than waves with lower frequencies.
1.4 Ultrasound beamforming
Ultrasound imaging is performed with short pulses of sound waves, instead of a
continuous transmission. In fact, transducers for diagnostic ultrasound are only very
briefly active, transmitting sound waves only during 0.1 - 2 % of the pulse repetition
period and register reflected signals during a much longer listening period. The
pulse duration, pulse cycle and number of pulses per time are important parameters
for the imaging process that influence imaging depth, resolution and frame rate of
real-time images.
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Figure 1.7: Simplified example of pulsed ultrasound imaging. Here, 3 short pulses with
3 cycles are shown. During the pulse repetition period, a short pulse is transmitted and
the transducer returns to quiescent stage and detects returning echos. A typical pulse
repetition period in diagnostic ultrasound lasts between 0.1 and 1 ms.
Modern transducers possess between 32-256 crystals depending on probe type and
imaging applications. These crystals are usually not excited as singular sequential
chain to generate waves with a single-point source. Instead, they are organized in
arrays, small groups of crystals, that can fire simultaneously and would results in a
straight ultrasound beam with straight propagation. Crystals of a single array can
be excited differentially as well, offering the possibility to focus and/or steer the
resulting wave front (see figure 1.8).
1
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4
Wavefront    
(a) Un-focused
1
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Wavefront
(b) Focusing
1
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4
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(c) Steering
Figure 1.8: The crystals in ultrasound transducers can be bundled into arrays and acti-
vated simultaneously, as it is shown here for a theoretical 4 crystal array.. (a) A Linear
pattern is achieved when the crystals are all excited simultaneously. The wavefront will
progress straight into the tissue. (b) Focusing of an ultrasound beam is achieved by dif-
ferential phasing of an array, which produces a focused wavefront with a focal point. (c)
Phasing of an array can also be used to steer the wave front.
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1.5 Ultrasound resolution
However, the existence of multiple sound waves at the same time will result in con-
structive and destructive interference that result in local amplification and extinction
of sound pressure levels. The beamforming, that is the control of interference pat-
terns in ultrasound imaging is complex but designed to generate optimal acoustic
pressure at the desired imaging point.
The resolution in ultrasound imaging rests on three pillars: spatial resolution, tem-
poral resolution and contrast resolution.
Spatial resolution is the ability of the ultrasound system to distinguish 2 different
structures at a certain depth. For ultrasound, the spatial resolution has 2 dimen-
sions: lateral (perpendicular to the imaging axis) and axial.
Unfocused transducers will transmit wavefronts that lead to huge amplitude change
close to the source, which is called near-field or Fresnel’s Zone (see figure 1.9). Fur-
ther away in what is termed far-field, the intensity will change less dramatically
and the ultrasound beam spreads. For medical ultrasound, transducers with a long
near-field are preferred, because the intensity as well as lateral resolution is higher,
which allows to distinguish two structures at a certain depth perpendicular to the
sound waves.
lateral resolution
Near Field Far Field
Unfocused Transducer
Figure 1.9: Here, two theoretical waves are drawn to show the interference patterns. Un-
focused transducer have a ”natural” focus point between a near-field (Fresnel’s zone) and
a far-field. The unfocused transducer can resolve laterally the green and red structures at
the near-field but fails to resolve blue and red in the far-field.
Focused transducers with their phased arrays will generate an ultrasound beam
with a focal zone (see figure 1.10). In this focal zone, the beam width is minimal
and the amplitude can be more than 100-fold higher compared to areas outside the
zone.
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Focal length
Focal region
Beam width
Focused Transducer
Figure 1.10: Focused transducers show a very narrow beam width at the focal region.
Smaller beam-widths increase the lateral resolution. The larger beam shown here in dashed
lines cannot resolve the two structures.
Axial resolution (or longitudinal) is the minimal spatial dimension between two
structures parallel on the imaging path that the ultrasound system can yet distin-
guish (see figure 1.11). It is determined by the frequency and the spatial pulse
length. Higher frequencies and shorter pulses yield a better resolution. The spatial
pulse length itself is defined by the number of cycles and the wavelength. There-
fore, axial resolution is best when high frequency transducers with a strong crystal
dampers are used. Unfortunately, these conditions favor strong attenuation as well
and thus limit the signal-to-noise ratio due to the dampening and ultimately the
penetration depth. However, the axial resolution does not vary with imaging depth
as the lateral resolution does.
axial resolution 
Pulse length
Focused Transducer
Figure 1.11: Focused transducers show a very narrow beam width at the focal region.
Smaller beam widths increase the lateral resolution. The axial resolution is determined
by the spatial pulse length (number of cycles, wavelength)
Temporal resolution of an ultrasound system depends on 3 factors: the number
of scan-lines, the depth of imaging and the number of focus points.
The wider the acquired frame is, the more scan-lines have to be used. By reducing
the image width, a frame can be acquired quicker and a next frame started earlier,
thus increasing the frame rate.
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The reduction of the imaging depth increases the possible frame rate as well, because
for each scan-line, the waiting period can be reduced to detect only signal to a certain
depth.
Multiple focus points have the side effect, that for each focus point, all scan lines
have to be duplicated which impacts the frame rate significantly.
Contrast resolution is determined by the acoustic differences of adjacent struc-
tures and the processing (digital sampling, compression) that results in a discernible
difference in intensity in an ultrasound image. The acoustic differences between tis-
sues can be very small so that there is no clear delineation in the anatomical ultra-
sound images. Application of ultrasound contrast agent will increase the echogenic-
ity of blood, which increases the contrast of the blood circulating in organs and
tissue.
The returning echoes that the ultrasound image is reconstructed from, can vary in
their amplitude over several magnitudes (> 1012). During the signal processing, this
acquired raw data is compressed to be stored and displayed. The ratio of the lowest
powered to the highest powered echoes is expressed as dynamic range
Dynamic range (dB) = 10× log10
(
highest power
lowest power
)
. (1.9)
Usually, the compression is selected between 30 dB to 60 dB which would translate
to a signal ratio of 1:100 to 1:1’000’000 respectively. The reconstructed images then
are stored as gray scale image sequences with a bit-depth of typically 8 bit, allowing
256 different values per pixel.
1.6 Ultrasound imaging modes
The most prominent mode of operation in medical imaging is the 2-dimensional B-
mode (or brightness-mode). B-mode offers a real-time image of brightness-modulated
echoes that originate from structures in the imaging plane.
In M-mode (or motion-mode) imaging, a single scan line is used to reconstruct a
1-dimensional B-mode image to assess motion of the tissue boundaries.
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In Doppler Mode, moving particles or structures can be characterized by their move-
ments. Measurements of frequency shifts in reflected echoes of moving particles
(predominantly erythrocytes) can be used to determine their velocities. The veloc-
ity information can then be presented as a color-coded overlay on B-mode images.
Red colors indicate particles moving towards the transducer and blue colors indi-
cating particles moving away (see Figure 1.12).
(a) A-Mode (b) B-Mode (c) M-Mode
transmitted
reflected
transmitted
reflected
v
v
(d) Pulsed-Wave Doppler Principle (e) Color Doppler Mode
Figure 1.12: Example of the display modes in ultrasound imaging. (a) A-Mode (Am-
plitude): For a single scan-line the echoes are plotted as a function of depth. (b) B-
Mode (brightness): 2-Dimensional representation of all acquired scan-lines formed into a
brightness-modulated image. (c) M-Mode (motion): B-Mode representation of a single
scan line (marked red) to monitor the tissue motion. (d) Pulsed-wave Doppler principle.
Ultrasound pulses will be reflected with a frequency shift depending on the movement of
the reflective particles. (e) Color Doppler Mode. Velocity information is presented as a
color-coded overlay on top of a B-mode image with red colors indicating moving particles
towards the transducers and blue colors indicating particles moving away.
Ultrasound Images from http://www.nysora.com
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1.7 Contrast enhanced ultrasound
Depending on the imaging conditions, some tissue-interfaces will have a similar
acoustic impedance. A liver for instance can present with a non-suspicious appear-
ance on anatomical B-mode images. However, when contrast agent is applied that
increases the echogenicity of blood and thus blood vessels, an extensively vascular-
ized liver tumor can become clearly visible as shown in figure 1.13
(a) Anatomical B-Mode (b) Contrast B-Mode
Figure 1.13: Ultrasound imaging of a liver tumor (a) without contrast agent or (b) with
a contrast agent. Images from Toshiba Medical Systems Europe.
The contrast agents used in ultrasound imaging are acoustically reflective parti-
cles like liposomes and nano-particles that possess small gas-pockets which increase
the particle’s echogenicity. The most common and effective contrast agent for ul-
trasound are microbubbles between 1-6 μm in diameter that possess a gas-filled core.
1.7.1 Structure of Microbubbles
Microbubbles as a contrast agent have been accidentally discovered by intra-cardiac
injections in the 1960s, when ultrasound images of the aorta showed a brief increase
in contrast. The effect was due to fine air-bubbles that have been formed at the
catheter tip while injecting. However, they were frail and disintegrated quickly by
coalescence, fragmentation and shrinking through diffusion.
By encapsulation with either proteins (e.g. albumins), polymers (cyanoacrylate) or
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by a phospholipid monolayer, the half life of the microbubbles increases dramatically
and can modulate specific properties regarding acoustic character, biofuntionality
or stability.
Shells consisting of polymers or proteins are characterized by their rigid character,
and although they expand and contract in a pressure field, the generated echoes are
of smaller intensity compared to microbubbles that possess a semi-fluid lipid-layered
shell. In addition, the use of lipid layer allows for a stoichiometric composition and
thus dynamic control over the properties of the shell even after the assembly of the
microbubble.
The use of functionalized lipids bearing biotin-, maleimide- or NHS-groups allows
the microbubble to have additional properties to the reflection of ultrasound waves.
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Figure 1.14: Microbubbles consists of a gaseous core surrounded by a shell made mostly
from proteins, polymers or phospholipids. They are between 1-6 μm in diameter. Se-
lective ligands can be attached to the microbubble shell via functionalized lipids as it is
shown here using biotin-streptavidin chemistry. Polyethylene glycol (PEG) chains form a
protective layer around the microbubble to prevent Ostwald ripening (fusion of microbub-
bles). The used gas usually has a high molecular weight and a low diffusivity and here,
Perfluorobutane (C4F10) is shown exemplary.
The gas-core optimally consist of an inert gas with a low diffusion coefficient and
low solubility in blood, for example sulphur hexafluoride or perfluorobutane.
Once microbubbles are assembled, the core-gas will diffuse slowly out of the mi-
crobubble across an osmotic gradient into the surrounding and the diameter of the
microbubble will decrease. For highly soluble gases like oxygen, nitrogen or carbon-
dioxide, the persistence is of several magnitudes shorter compared to large molecule
gasses.
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Figure 1.15: Microbubble persistence in vivo depending on the core gas. Gases with
lower diffusion coefficient (e.g. Perflurcarbons) show a slower microbubble shrinking due
to loss of internal gas pressure than gases with a higher coefficient (e.g. Nitrogen).
1.7.2 Microbubble behaviour in an ultrasound field
When microbubbles are placed in an ultrasound field with periodically changing
pressure, they start to oscillate by cyclic expansion and compression. The degree of
oscillation is dependent on the frequency of the incident ultrasound beam and the
acoustic intensity. An individual microbubble has a specific resonant frequency at
which it will oscillate most effectively.
This frequency does show an inverse hyperbolic relation to the microbubble diam-
eter and is further determined amongst others by the microbubbles shell-elasticity
and the surrounding dampening.
Linear oscillation
In pressure fields with low acoustic power insonation of a peak pressure <100 kPa,
microbubbles will oscillate in a linear manner with the same frequency as the exciting
soundwave (see Figure 1.16a).
The back scatter that will be detected at the transducer will be of several mag-
nitudes higher than the back scatter from red blood cells thus opacifying the blood
but the signal will not differ qualitatively, thus backscatter is only enhanced.
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Non-linear oscillation
Within pressure fields of moderate intensities of peak pressures between 0.1-1 MPa,
microbubbles will show non-linear behavior (see Figure 1.16b). Gas-filled microbub-
bles will expand in low pressure much quicker and to a greater extent than they can
be compressed under high pressure and thus will stay longer in a expanded state.
Because of its non-linear behavior, a microbubble will have a different diameter
each time it encounters the periodically reoccurring pressure maxima and minima.
This will lead to a different backscatter and applied force on the shell that will
influence the oscillatory behavior.
Another effect of this non-linear behavior is the generation of harmonic and sub-
harmonic oscillations that microbubbles can undergo as well. This behavior will
result in backscattering of sound wave at multiples (harmonics) and half (sub-
harmonics) of the incident fundamental frequency.
Disruption
If the incident ultrasound beam exceeds a pressure >1 MPa, the microbubble will
oscillate in an erratic manner and the forces lead to a shell rupture and microbubble
destruction (see Figure 1.16c).
r rr rr
Microbubble radiusPressure
Time
(a) Low pressure
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Figure 1.16: Microbubble behaviour in a cyclic pressure field. (a) Under low acoustic
power insonation, a microbubble will oscillate with a linear change of its radius. (b) With
higher pressure however, the behaviour of a microbubble becomes non-linear and it will
produce a harmonic response as well. (c) With further pressure increase, the microbubble
will start oscillate erratically and will eventually burst.
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1.7.3 Contrast enhanced ultrasound imaging techniques
The resulting back-scatter from microbubbles are thus special in at least two ways:
they show a complex intensity pattern that will differ from linear responses of tissue
and they show harmonic and sub-harmonic components. For contrast-enhanced
ultrasound imaging, various strategies are possible that utilize these differences.
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Figure 1.17: Differences of signals from tissue and microbubbles. (a) Intensity of an
incident sound pulse over time that will produce returns originating either from tissue or
microbubbles. (b) The intensity of echoes from tissue resemble the linear oscillation of
the incident soundwave while the signal from microbubbles show non-linear and irregular
intensity changes. (c) The frequency spectrum for tissue will show a single peak at the
fundamental frequency fc of the incident sound wave while the spectrum for microbubbles
will show sub-harmonic ( 1n fc) and harmonic (nfc) components as well.
Cadence Contrast Pulse Sequencing (CPS) Technology
Cadence contrast pulse sequencing (CPS) is a advanced ultraound imaging protocol
to distinguish acoustic signals from microbubbles and tissue. The imaging protocol is
based on three principles: pulse inversion, power modulation and harmonic imaging.
In CPS, three successive ultrasound pulses are transmitted with a second pulse
that is special in two ways.
Firstly, the second pulse at t2 has a phase of 180
◦ compared to the first and third
pulse at t1 and t3 respectively, which is called pulse inversion.
Secondly, the second pulse at t2 has a amplitude that is exactly twice as high com-
pared to the first and third pulse at t1 and t3 respectively, which is called power
modulation.
The backscatter from for these three pulses will be combined according to the
travel time. For tissue, with a predominating linear response, the signals will cancel
each other out, resulting in no signal after the combination. For microbubles, how-
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ever, their complex backscatter that is caused by the non-linear behavior will result
in a clear signal that differentiates the signals received from microbubbles.
For harmonic imaging, the same principle will result in an eliminated signal after
combination for tissue, but in a clear signal for microbubbles.
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Figure 1.18: Simplified imaging protocol for Cadence contrast pulse sequencing used to
differentiate signal of microbubbles from tissue.
A sequence of three pulses are transmitted. The second pulse at t2 is inverted by 180
◦
with an amplitude twice as high as t1 or t3.
Signals with the same travel time are combined and total results for tissue are canceled out.
Microbubbles produce a complex backscatter due to their non-linear behavior, including
phase shift, that results in a signal after calculation.
The tissue react mostly with the fundamental frequency of the transmitted sound-pressure
and show no harmonic behaviour. Microbubbles, however, oscillate not only with at the
fundamental, but also at harmonic and sub-harmonic frequencies that can be utilized as
well to detect backscatter originated from microbubbles.
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1.7.4 Requirements of contrast enhanced ultrasound agents
In ultrasound molecular imaging there are specific requisites both for the targeted
contrast agents as well as the targeted epitopes (see figure 1.19).
The epitopes that can be targeted with microbubbles are limited to the endothelial
surface, because the diameter of microbubbles prevents them to pass the endothelial
barrier. However contrast enhanced ultrasound of extravascular epitopes is possible
with the use of echogenic liposomes or perfluorocarbon nanoparticles. The epitopes
in question optimally is specific for the disease or condition and is not expressed
ubiquitously in the whole vascular system.
The targeted contrast agent optimally has a high ligand density on its surface to
maximize adhesive bonds. For optimal imaging results, the ligand itself needs to
have a high affinity to facilitate quick binding to its target and a high specificity
to minimize cross-reactivity. The ligand:epitope interaction is vital for the targeted
imaging process and inhibitors or proteases that reduce the ligands capabilities to
bind the epitope or shear forces that prevent the molecular interaction will decrease
the specific molecular imaging signal.
Targetet Agent Properties
- high density ligand on surface
- ligand with high aﬃnity and speciﬁcity 
  for targeted molecule
- absence  of competitive inhibitors 
Hemodynamic Properties
- shear forces
Target Molecule Properties
- speciﬁcity for disease 
- limited constitutive expression
- presence on endothelial surface
Figure 1.19: Requirements for molecular ultrasound imaging. The targeted agent op-
timally has a high density ligand on its surface with high affinity and specificity for the
epitope in question.
The targeted molecule (epitope) optimally is specific for the disease and has a limited
expression. Only epitopes present on the endotheliala surface can be targeted by mi-
crobubbels with a diameter of >1 μm.
Least, the contrast agent has to be able to tolerate the shear forces present in the vascu-
lature at least for a short term to allow imaging.
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1.7.5 Application protocols for contrast enhanced ultrasound
Contrast enhanced ultrasound can be used to answer several questions. For example
it can be used to opacify the microvasculature in organs to assess a malignant devel-
opment. The imaging can be performed after a short latency to allow a homogeneous
distribution of the contrast agent.
However, the use can be extended beyond backscatter enhancement.
Dynamic assessment in perfusion imaging
When the injected microbubbles are homogenously distributed in the circulation,
the signal enhancement is evident in almost every tissue. But taking advantage by
the vulnerability of microbubbles, they can be strategically destroyed in an imaging
plane.
One application is the perfusion imaging of a tissue to assess blood flow.
time
signal intensity
A
A*β
E
Destruction
Figure 1.20: Intensity function of
myocardial perfusion in a tissue vol-
ume penetrated by ultrasound beam
with elevation width E. Intensity
plateau A is re-established after de-
struction with an initial blood flow
represented by A×β.
In echocardiography, the quantification of blood
volume and blood flow in the myocardium can be
achieved by a continious injection of microbub-
bles to ensure a homogeneous distribution in the
circulation. The image intensity in an assessed
tissue volume will be constant at an intensity
platea (see figure 1.20). Several high intensity
ultrasound pulses with a maximum MI of 1.9
can now be used to destroy all microbubbles
present in the imaging plane and the signal in-
tensity will be severely reduced. When the inten-
sity is minimal, the contrast enhanced imaging
will be switched to a lower MI to allow a non-
destructive imaging. The blood flow will bring
new microbubbles into the imaging plane and af-
ter a period of time the plateau intensity will be
reached again because the microbubble pool in the circulation is undisturbed by the
locally applied destruction pulses. By monitoring the dynamical signal increase over
time, the plateau and the rate of replenishment can be quantified.
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Assessment of signal in ultrasound molecular imaging
Targeted microbubbles can be used to assess the expression of an epitope on the
endothelial surface with the use of non-invasive ultrasound.
A bolus of targeted microbubbles is injected into the circulation and a subsequent
latency of 5-10 minutes allows a homogeneous microbubbles distribution throughout
the circulation. During the equilibration time, targeted microbubbles that have been
conjugated with a ligand or are assembled with a specific shell element will adhere
to their specific target. The amount of free floating microbubbles on the other hand
will be reduced over time through phagocytosis by hepatic kupffer cells.
The total video intensity of a taken ultrasound image is the sum of signals generated
both from adhered and freely circulating microbubbles (see figure 1.21).
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Figure 1.21: Schematic representation of molecular imaging. A bolus injection of mi-
crobubbles will increase the total signal intensity. A period of 8 minutes allowed adhesion
of microbubbles. A pre-destruction frame was captured before a high pressure ultrasound
pulse during multiple frames was used to destroy all microbubbles in the imaging plane.
Molecular imaging data of adhered microbubbles were determined by the difference of pre-
and post-destruction frames.
To assess the video intensity that is generated by adhered microbubbles alone,
an inverse approach is used. A pre-destruction frame is acquired that consists of
both signals generated from adhered as well as freely circulating microbubbles. All
existing microbubbles in the imaging plane will be destroyed by application of mul-
tiple high intensity ultrasound pulses to ensure total destruction all microbubbles in
the imaging plane. The total amount of microbubbles freely circulation is of several
magnitudes higher than the number of microbubbles in the imaging plane, so that
the reservoir of circulating microbubbles is not affected by a destructive pulse over
a short period.
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After the destruction period, a post-destruction frame is recorded that does consist
predominantly of signal from freely circulating microbubbles in the tissue and will
serve as a base-line. Subtraction of pre- and post-destruction frames will yield the
signal intensity of adhered microbubbles.
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2 Contrast Imaging in acute
Myocarditis
2.1 Introduction
Myocarditis is defined as inflammatory infiltration of the myocardium with myocyte
degeneration and necrosis in the absence of ischemia [1]. It has been found in 1-9%
of routine autopsies [2], and in a higher proportion (5-12%) in young individuals
with sudden unexplained cardiac death[3]. This is in contrast to the perceived low
frequency of a diagnosis of myocarditis in patients.
Myocarditis can be caused by a variety of infectious agents, including viruses, bac-
teria or other pathogens but can as well be secondary to autoimmune pathologies
and other exposures like systemic diseases, drugs and toxins [4] (see Table 2.1).
The most frequent cause for myocarditis are cardiotropic viruses 2.1 [5, 6] with
Coxsackie B3 being responsible for half of the observed cases. Interestingly, only few
viruses inflict direct cardiomyocyte damage. For example Coxsackie virus B3, which
infects a variety of cell types including lymphocytes, macrophages, fibroblasts and
cardiomyocytes and leads to virus-mediated cell-lysis. Virus-mediated cell lysis and
more importantly the ensuing immune response that is targeted against infected
cardiomyocytes [7] leads to a pro-inflammatory milieu that amplifies myocardial
tissue damage and dysfunction.
In contrast, most viruses induce myocardial damage only indirectly via inflammatory
pathways. For example, HIV or Parovirus B19, that predominantly infect T-cells
and macrophages or endothelial cells, respectively [8] do not lead to direct myocyte
damage.For these viruses, the exact link between infection and myocardial damage
is less well understood but autoimmune processes seem to be the decisive.
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Table 2.1: Various causes of Myocarditis. Adapted from Sagar et al. [4]
Causes Etiologies
Viral Coxackievirus, Adenoviruses, HIV, Hepatitis C virus,
Parvovirus B19, Influenza viruses
Bacterial Legionella, Mycobacterium tuberculosis, Corynebac-
terium diptheriae, Staphylococcus aureus
Fungal Candida, Aspergillus
Parasitic Trypanosoma cruzi, Toxoplasma gondii
Autoimmune diseases Giant cell myocarditis, Rheumatoid arthritis, Celiac dis-
ease, Sarcoidosis, Scleroderma
Hypersensitivity Allergic reactions e.g. against Penicillin,
Toxins Ethanol, Arsenic, Chemotherapeutic agents
2.1.1 Pathogenesis of Myocarditis.
Most of our understanding of myocarditis has been gained by work on animal mod-
els, specifically on small rodents. The artificial induction of myocarditis can be
achieved in laboratory models by either infecting the mice with cardiotropic viruses
(e.g. Coxsackie B3) or challenging the immune system with self-peptides (e.g. car-
diac myosin) to induce cardiomyocyte damage. In the latter, the immune system
is activated by a challenge with strong boosting adjuvants that maximize the cell-
mediated immune reaction (e.g. inactivated mycobacteria in mineral-oil). To opti-
mize the induction rate, the animals usually are treated prior to peptide-vaccination
with Pertussis toxin to induce lymphopenia in the CD4+CD25+ regulatory T-cell
population to remove their dampening control on B- and T-cell effector function [9].
Acute Phase. In the acute phase of virus-induced myocarditis (see figure 2.1),
infected cardiomyocytes are recognized by natural killer cells and driven into apop-
tosis. The first line of defense are residing macrophages, dendritic cells and a wave
of invading neutrophil and natural killer cells that help clearing the virus and cell
debris. This innate mechanism helps to control the virus titer effectively but due
to the secretion of granzyme and perforin and the accumulation of cell debris, the
surrounding myocardial tissue can be damaged extensively.
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Figure 2.1: Stages of myocarditis. In the pathogenesis of myocarditis, direct viral injury
during the acute phase and the ensuing host immune response with leukocyte infiltration
during the subacute phase can lead to dilated cardiomyopathy with fibrosis and reduced
systolic function in the chronic phase. CD4 positive T-lymphocytes are crucial in mediat-
ing the autoimmune response in the subacute phase by secreting interleukin 17.
Residing dendritic cells and macrophages detect pathogens with pattern recog-
nition receptors (e.g. Toll-like receptors, C-type lectin receptors etc.) and secrete
pro-inflammatory soluble mediators, most importantly TNFα, IL-6, Nitric oxide and
IL-1, which can worsen tissue damage further [10].
The expression of TNFα, IL-6, and IL-1β was found to be essential for develop-
ment of EAM [11]. One specific action of TNFα in the autoimmune processes is
the increased activation of residing dendritic cells that have a central role in the
pathogenesis of myocarditis .
Subacute Autoimmune Phase. The immune response has as its goal virus clear-
ance and it has been shown that with viral persistence is much worse (requirement
for transplantation, sudden death) [12] Once viral reproduction is controlled, the
immune system should be down-regulated.
However, due to the intense inflammatory milieu and non-specific cellular damage,
certain processes can initiate auto-immune pathways. Although the processes in-
volved are less well understood, they include collateral activation of auto-reactive
CD4+ T-cells and molecular mimicry of virus antigens. Here, epitopes are shared
between virus and cardiac proteins or polysaccharids that trigger T-cell activation
against intrinsic self-antigens. Virus antigens may also trigger a predominant re-
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sponse that activate more CD8+ cytotoxic T-cells that additionally fuel the im-
munologic circle, which leads towards auto-immunity and is usually driven by Th1
cells [13].
Figure 2.2: Role of dendritic cells in Myocarditis. The interaction of CD4+ cells with DC
via the antigen:T-cell receptor axis and a survival-signal via CD40:CD40 Ligand axis can
lead to the expansion of auto-reactive B- and T-helper cells and a prolonged CD8+ T-cell
activity. Pro-inflammatory cytokines as TNFα, IL-1, IL-6 and IL-12 keep the activation
on a persistent level. Adapted after [14].
The cytokine profile in the inflamed spots however, is dominated by TNFα, IL-6,
-1, -12, -23, IL-4 and -17, secreted predominantly by natural killer cells, dendritic
cells and macrophages. With the influx of T-cells, that is initiated around day 7 in
the induced animal models and peaks around day 21, the cytokine profiles would
determine a shift to either a Th2 response (B-cell activation, humoral immunity,
IL-4, -5 , -10 and IgE production) or a Th1 response (hypersensitivity, macrophage
activation, pro-inflammatory T-cell response with IFN-γ and IL-12) [15].
However, the balance of pri... (alte text) is variable for at least two reasons
First, there seems to be a differences between animals with genetic background in
models of myocarditis, regarding the pathological severity and prevalence. Induced
autoimmune myocarditis provokes a Th2 cytokine profile in A/J mice that can be
blocked with anti-IL-4 antibody [16], while in other strains or in lewis rats myocardi-
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tis is promoted by a Th1 response [17]. Similarly, female BALB/c mice lacking the
IL-4 receptor are not protected against the development of myocarditis, which is in
contrast to the findings in A/J mice. This might be partially be explained due to
the different H2 haplotypes (BALB/c: H2d; A/J: H2k [18]).
Second, the general mechanisms of trans-inhibition of the opposite Th response is
disturbed in autoimmune diseases and other subsets of CD4+ cells, namely Th17 and
especially Tregs are regulated differently in autoimmune myocarditis. The classical
Th2 cytokine IL-10 or the Th1 primary cytokine Interferon γ have an inhibitory
effect that prevent the development of myocarditis and show overlapping expression
as well.
Pro-inflammatory cytokines like IL-4 and IL-1 have been shown to play a major
role in expansion and differentiation of auto-reactive CD4+ T-cells in presence of
professional antigen-presenting cells [19], most importantly dendritic cells. IL-1β ex-
pression additionally correlates with fibrotic lesions that leads to dilated cardiomy-
opathy and an increased heart weight in the chronic phase [20].
Figure 2.3: Development of Myocarditis. Adapted from Leuschner et al. [21]
Dendritic cells also express IL-12 and most importantly its closest relative IL-
23. Both play a crucial role in activation and differentiation of CD4+ Th17 T-cells,
an important subset involved in pathogenesis of myocarditis [22]. IL-23 knock-
out animals appear to be resistant against the induction of myocarditis and in those
animals, transplantation of α-myosin specific CD4+ Th17 cells are sufficient to induce
autoimmune myocarditis [23]. The effector function of CD4+ Th17 cells includes the
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broad induction of many pro-inflammatory chemo- and cytokines and prostaglandins
that increase the cellular influx of monocytes and neutrophils into the myocardium
significantly.
The effect of Th17 activation in this scenario is the initiation of a delayed-type
immune reaction that is not terminated despite pathogen clearance.
Chronic phase with dilated cardiomyopathy. Ongoing inflammation in the my-
ocardium can lead to severe tissue damage. Myocytes are replaced with connective
tissue. On the one hand this leads to a decrease in myocardial elasticity and thus to
impaired ventricular filling during diastole. On the other hand, loss of myocytes and
thus a reduction of contractile elements leads to systolic dysfunction. Together, sys-
tolic and diastolic dysfunction lead to left ventricular filling at increased pressures,
dilatation of the left ventricle with increased wall tension. Increased wall tension is
counterbalanced by myocyte hypertrophy which worsens diastolic function. Thus,
a vicious cycle is started which results in further dilatation and the development
of dilated cardiomyopathy. In the clinical field, dilated cardiomyopathy is defined
as a left ventricular volume above the 99th percentile of values encountered in a
normal population, whereas a reduction in systolic function is generally defined as a
reduction of the left ventricular ejection fraction below 45%. Dilated cardiomyopa-
thy with reduced ejection fraction leads to clinical signs of heart failure (dyspnea,
impaired exercise tolerance) and can result in the necessity for heart transplant.
Due to arrhythmias, dilated cardiomyopathy can result in sudden cardiac death.
2.1.2 Diagnosing Myocarditis.
The clinical presentation of myocarditis is highly variable, and symptoms can even
be absent. If present, symptoms can be non-specific (eg. fatigue, fever, dyspnea,
chest pain). Routine cardiac tests either lack sensitivity (e.g. ECG) or specificity
(e.g. troponins) for diagnosing myocarditis. The endomyocardial biopsy (EMB) is
considered the gold standard to confirm the diagnosis of a suspected myocarditis
[24]. However, EMB is invasive and suffers from low sensitivity and a high inter-
observer variability in interpretation [25].
Thus, there is a need for non-invasive imaging methods for the diagnosis and de-
tailed characterization of myocarditis. Echocardiography, radionuclide imaging and
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cardiac magnetic resonance (CMR) imaging have all been used for the detection of
myocarditis in clinical and pre-clinical studies.
Echocardiographic features of myocarditis include left ventricular dilatation, seg-
mental wall motion abnormalities, increased left ventricular sphericity and transient
increases in left ventricular wall thickness [26–28] but unfortunately are limited in
diagnostic accuracy.
For nuclear imaging, Indium-111 radiolabeled anti-myosin antibodies have been used
for the detection of myocardial necrosis in murine models of myocarditis and in clin-
ical studies [29, 30]. CMR imaging allows detection of myocardial edema or irre-
versible tissue damage inflicted by the inflammatory infiltrate [31, 32] but sensitivity
is variable and may be reduced in the absence of tissue necrosis [33].
Recently, fluorine-19 CMR has been used for detecting the inflammatory infiltrate
in murine autoimmune myocarditis [34].
Thus, with the exception of fluorine-19 CMR, a common weakness of the afore-
mentioned techniques is that they detect tissue injury (edema, necrosis), which can
also be due to, for example, myocardial ischemia rather than the inflammatory in-
filtrate.
Animal models of both virus-induced and autoimmune myocarditis suggest that
heart-specific auto-aggressive inflammatory responses are important in the develop-
ment of chronic cardiomyopathy after acute viral infection, and that CD4+ lympho-
cytes are instrumental in driving these processes [7, 13, 35].
2.1.3 Ultrasound molecular imaging in myocardial tissue
In the last years, microbubble ultrasound contrast agents have been modified for
the purpose of molecular imaging. Either modifications in the shell properties or
the conjugation of specific ligands to the microbubble shell surface have been suc-
cessfully used to promote adhesion of microbubbles to disease-specific events on the
endothelial surface of blood vessels.
The feasibility of this strategy for molecular imaging in the myocardium has been
proven in vivo with targeted microbubbles against P-Selectin. In the ischemic my-
ocardium, the endothelial cells react very quickly to the disturbed blood supply and
increase in cellular stress (e.g. reduction of pH, oxidative stress). One result of the
induced endothelial dysfunction is the rapid exposure of leukocyte-specific adhesion
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molecules and chemokines that are stored in Weibel-Palade bodies, predominantly
P-Selectin and IL-8. The increase of P-Selectin on the endothelial surface is fa-
cilitated within minutes and can prevail on elevated levels even after resolving of
ischemia, a phenomenon called ischemic memory of the endothelium. Microbubbles
targeted to P-Selectin either using a monoclonal antibody or the P-Selectin ligand
sialyl Lewisx were successfully used to identify ischemic myocardium [36, 37].
2.1.4 Aim of the study.
In this study, we therefore hypothesized that contrast enhanced ultrasound (CEU)
molecular imaging can be used to detect (1) the inflammatory cell recruitment and
endothelial inflammatory activation, and (2) the recruitment of CD4+ lymphocytes
in a murine model of myocarditis.
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2.2 Material & Methods
2.2.1 Study design and animal model
All experiments were performed in accordance with Swiss Federal Legislation and
were approved by the Animal Care Committee of the Canton of Basel. A total of
48 female BALB/c mice were used for this study.
Imaging of the acute phase in Myocarditis. In 44 mice, experimental autoim-
mune myocarditis (EAM) was induced by intra-peritoneal injection of 400 ng Per-
tussis toxin (List Biological Laboratories, Campbell CA) followed one hour later
by subcutaneous injection of 120 μg of αMyHC peptide (α myosin heavy chain,
Ac-RSLKLMATLFSTYASADR-OH, GeneCust, Dudelange, Luxemburg) emulsified 1:1 v/v
with complete Freud’s adjutant (CFA, Sigma Aldrich, Buchs, Switzerland) on day
0. On day 7, the animals were re-challenged with an αMyHC peptide injection. 4
animals injected with saline/CFA served as controls. The immunization with this
particular αMyHC peptide results in development of EAM in about 60% of injected
animals with an inflammatory infiltrate that peaks around day 21.
Pertussis Toxin i.p.
Cardiac 
Saline
myosin heavy chain s.c.
9 weeks 10 weeks 11 weeks High frequency ultrasound imaging
Ultrasound molecular imaging
Histology, Immunohistology9 weeks 10 weeks 11 weeks 
Figure 2.4: Study design. Animals were challenged with 2 injections containing cardiac
α-myosin peptide and analyzed 3 weeks after induction of experimental autoimmune my-
ocarditis. Control animals, that did not receive α-myosin peptide injections were analyzed
as well. The animals were sacrificed after the analysis on day 21 and tissue was collected
for histology.
Assessments at day 21 included:
Day 21 imaging acute phase
• high frequency ultrasound imaging including strain imaging,
• ultrasound molecular imaging targeting leukocytes, P-Selectin and CD4+ lym-
phocytes as well as
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• measurement of myocardial perfusion
• histology and immunohistology.
Histology of the hearts at the mid-ventricular level was performed for assessment of
myocarditis severity and immunohistology was used to quantify CD4+ lymphocytes
in the tissue.
2.2.2 Microbubble Preparation
Perfluorocarbon-filled, lipid-shelled microbubbles were prepared by sonification of
a gas-saturated aqueous suspension of distearoyl-phosphatidylcholine (2 mg/ml;
Avanti Polar Lipids, Alabaster AL, USA) and polyoxyethylene-(40)-stearate (1 mg/ml;
Sigma-Aldrich, Buchs). These non-targeted microbubbles were used for the assess-
ment of myocardial perfusion. Microbubbles for targeting of leukocytes (MBLc) were
prepared by adding distearoyl-phosphatidylserine (0.3 mg/ml; Avanti Polar Lipids)
to the aqueous suspension before sonification [38].
For targeting of P-Selectin and CD4, distearoyl-phosphatidylethanolamine- PEG(3400)-
biotin (0.14 mg/ml; Creative PEG Works, Chapel Hill, NC, USA) was added to
the lipid suspension. Microbubbles targeted to P-Selectin (MBPSel) and to CD4
(MBCD4) were then prepared by conjugation of biotinylated anti-P-Selectin antibody
(RB40.34, BD Bioscience) or anti-CD4 antibody (H129.19, BD Bioscience) to the
microbubble surface using biotin-streptavidin-biotin linking as previously described
[39]. Control microbubbles (MBIso) bearing a non-specific isotype control antibody
(R3-34, BD Bioscience) were also prepared. Microbubble concentration and size were
measured by electro-zone sensing (Multisizer III, Beckman-Coulter). Microbubble
mean size was not statistically different for the three microbubble preparations (2.7
±0.2 μm for MBIso, 2.5 ±0.2 μm for MBLc, 2.7 ±0.2 μm for MBPSel, 2.7±0.2 μm for
MBCD4; p=n.s.).
2.2.3 In vitro assessment of microbubble-CD4 interaction
Flow chamber experiments were used to assess the specific attachment of MBCD4
to CD4 protein under flow conditions. CD4+ protein was adsorbed to culture dishes
(35mm, Corning, Corning NY) at a concentration of 5 ng/μl by overnight incubation
at 4◦C. The dishes were then washed with PBS containing 0.05% Tween 20 and
blocked with 1% albumin in PBS/0.05% Tween 20 for 1 hour at room temperature.
35
Figure 2.5: Schematic of the
used parallel plate flow chamber
coated with CD4 protein.
The culture plates were mounted on an inverted
parallel plate flow chamber (Glycotech, Gaithers-
burg, MD, USA) with a gasket thickness of 0.127
mm and a channel width of 2.5mm. The flow cham-
ber was placed in an inverted position on a micro-
scope (Olympus BX51W). A suspension of either
MBCtr or MBCD4 at a concentration of 3× 106ml−1
was drawn through the flow chamber at a shear
rate of 2 dynes/cm2. After five minutes of continu-
ous flow, the number of attached microbubbles was
counted in 40 randomly selected, non-overlapping
optical fields (20× magnification, total area 2.94
mm2). Experiments were carried out in triplicate.
CD4
-
CD4+
Figure 2.6: CD4− or CD4+
cells incubated with MBCD4
A cell-based adhesion assay was used to deter-
mine whether MBCD4 specifically attach to lympho-
cytes expressing CD4. Single cell suspensions of
murine spleen cells from 4 mice were generated us-
ing a cell strainer (40 μm, nylon, BD Falcon 352340).
CD4+ T cells were enriched in the cell suspension
by depletion of magnetically labeled non-target cells
using a cocktail of biotin-conjugated monoclonal an-
tibodies and anti-biotin MicroBeads (CD4+ T Cell Isolation Kit II, Miltenyi Biotec)
according to the manufacturer’s instructions. Both the separated non-target cells
and the CD4+ cells were resuspended at a concentration of 2× 107 cells per 100 μl.
Static preparations of either 1 × 106 CD4+ leukocytes or CD4− leukocytes respec-
tively were then incubated with 1 × 107 microbubbles (MBCtr or MBCD4) at room
temperature for 10 minutes followed by washing with PBS twice. Cells were counter
stained with nuclei-specific Hoechst 33342 (ThermoFischer, Reinach). Microscopy
at 20× magnification (Zeiss LSM 710) was used to assess microbubble attachment
to the cells.
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2.2.4 Animal instrumentation
On day 21 after immunization the mice were anesthetized with 5% isoflurane, which
was subsequently reduced to 2% and adapted to stabilize the heart rate between 350
and 450 bpm. The animal core temperature was maintained at 37 ◦C at all times by
the use of a temperature controlled heating stage. Chest and neck were depilated
with a chemical hair remover and cleaned thoroughly. For microbubble injections,
the right internal jugular vein was cannulated with a 0.97 mm polyethylene tubing
(PE-50, BD Diagnostics).
The animals were then transferred onto a temperature-regulated imaging stage (Vevo
Imaging Station).
2.2.5 2-dimentional and M-Mode Echocardiography
Figure 2.7: Assessment of wall
thicknesses in M-Mode images. Dif-
ferences of diastole and systole were
averages of three measurements.
High frequency (40MHz, MS 550D transducer)
ultrasound imaging (Vevo 2100, VisualSonics
Inc., Toronto, Canada) was performed for assess-
ment of cardiac structure and function.
M-Mode images of the left ventricle at the height
of the papillary muscles were used to measure an-
terior and posterior wall thickness, left ventric-
ular diameter both during systole and diastole
(see Figure 2.7).
Left ventricular ejection fraction (EF) and left
ventricular mass were derived from these mea-
surements as described previously [40].
E-wave and A-wave velocities were measured us-
ing pulse-wave Doppler tracings from a modified
apical 4-chamber view to assess flow across the
mitral valve.
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Strain imaging
Usually, left ventricular ejection fraction assesses systolic function accurately. How-
ever, the ejection fraction does depend as well on the ventricular contractility and
pre- and after-load. Therefore, other measurements that assess contractile function,
have been developed.
Strain imaging is a method in echocardiography to assess deformation of the con-
tracting and relaxing myocardium over time. That is of importance, because in
myocardial ischemia or infarction, parts of the myocardium will have reduced sys-
tolic function through transient or permanent impairment of their contractile capa-
bilities. A passive area however can appear moving fully functionally in a B-mode
exam through forces exerted by surrounding segments. Strain imaging is especially
useful in these situations, because the whole myocardium in the imaging plane can
be tracked for its deformation and nonfunctional areas can be identified.
Strain imaging can be performed either by tissue doppler or by speckle tracking
echocardiography. Speckle tracking is based on interference patterns (speckles)
within the myocardial tissue that can be tracked between at least two frames in
B-mode images. These unique patterns are being tracked between frames and a
global vector map of the myocardial tissue will be generated with information about
velocities and directions for every point in the myocardium over time. In that way,
the myocardial tissue deformation and movement can be assessed and quantified.
For strain measurements, parasternal long- and short-axis B-mode images were
acquired at a frame rate of >200 frames per second. Longitudinal, radial and cir-
cumferential global peak strain values were derived from the B-mode images using
a speckle tracking algorithm (VevoStrain, VisualSonics) [41].
Briefly, cine-loops with two cardiac cycles not distorted by respiratory movements
were selected and the endocardial and epicardial borders were traced on end-diastolic
frames (see Figure 2.8). After automated tracing, manual adjustments were made
as necessary for good tracking throughout the cardiac cycles. The strain measure-
ments were then averaged over the two cardiac cycles without the use of temporal
smoothing filters.
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Longitudinal
RadialCircumferential
(a) (b)
Figure 2.8: (a) Strain in three dimensions. Measurements were performed in the short
axis imaging plane (radial & circumferential strain) and in the long axis imaging plane
(longitudinal strain). (b) Exemplary strain measurement of the endocardium in the short
axis plane. After tracing the region of interest, motion vectors are calculated based on
specle-noise movements in the tissue. An average of all 6 segments is then calculated for
the whole endocard in the particular imaging plane.
2.2.6 Contrast Enhanced Ultrasound Imaging
Contrast ultrasound imaging (Sequoia Acuson C512; Siemens Medical Systems USA
Inc., Mountain View, CA) was performed with a high-frequency linear-array probe
(15L8) held in place by a railed gantry system. The left ventricle was imaged in
short axis at the papillary muscle level from a left parasternal window. ECG-gated
triggering was used to acquire end-systolic frames. For the detection of the contrast
agent, power modulation and pulse inversion (Contrast Pulse Sequence) imaging at
a centerline frequency of 7 MHz and a dynamic range of 50 dB was used.
Molecular CEU imaging.
The gain settings were adjusted to levels just below visible noise speckle and held
constant. MBIso, MBLc, MBPSel, or MBCD4 (3×106 microbubbles per injection) were
injected intravenously in random order. Ultrasound imaging was paused from the
time of injection until eight minutes later when imaging was resumed at a mechanical
index of 0.87. The first acquired image frame was used to derive the total amount
of microbubbles present within the left ventricular myocardium.
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The microbubbles in the ultrasound beam were then destroyed with several (>10)
high intensity image frames with a mechanical index of 1.9. Several image frames at
a long pulsing interval (every 9 heartbeats) were subsequently acquired to measure
signal attributable to freely circulating microbubbles. After log-linear conversion
using known dynamic range lookup tables, frames representing freely circulating
microbubbles were digitally subtracted from the first image to derive signal from
attached microbubbles alone. Contrast intensity was measured from a region of
interest encompassing the whole left ventricular myocardium. The selection of the
region of interest was guided by fundamental frequency anatomic images of the
left ventricle acquired at 14 MHz at the end of each individual imaging sequence.
In 7 additional animals with myocarditis, imaging was performed 10 minutes after
blocking of CD4 by intravenous injection of anti-mouse CD4 mAb (H129.19, BD
Bioscience, 5μg).
Myocardial perfusion After CEU molecular imaging, microvascular perfusion was
assessed using constant infusions of non-targeted microbubbles at an infusion rate
of 3 × 106 microbubbles per minute. A high energy destruction impulse spanning
5 frames with a mechanical index of 1.9 was performed to destroy all microbubbles
in the image plane. End-systolic short-axis image frames of the left ventricle were
acquired over several heartbeats (>10) at a low mechanical index of 0.2.
On the resulting destruction-replenishment sequences, the average signal intensity
of the myocardium was fitted to the mono-exponential function f(t) = A(1− e−βt),
where f(t) is the signal intensity at a given time point, β is the rate of rise of the
curve, and A is the plateau intensity. Myocardial blood flow (MBF) was estimated
by the product of A×β [42].
2.2.7 Histology and immunohistology
Two 5μm thin tissue slices at the height of papillary muscles where the contrast-
enhanced ultrasound imaging was performed were processed for histological analysis.
For the assessment of myocarditis severity, Hematoxylin and Eosin stained short axis
cross-sections of the hearts were analyzed by an independent pathologist blinded
for all other experimental data. Myocarditis was assessed following an accepted
guidelines [35] on a scale ranging from 0 to 4 by a pathologist blinded to animal
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treatment.
score 0 representing no inflammatory infiltrate
score 1 small foci of leukocytes between cells
score 2 larger foci of >100 leukocytes
score 3 >10% of the cross section involved
score 4 >30% of the cross section involved
For immunohistochemistry, snap frozen heart sections were stained with antibod-
ies for CD4 (MCA4635T, AbD Serotec).A fluorescent secondary antibody (A-11006
Alexa 488, Invitrogen) was used to visualize CD4, and the cells per mm2 of tissue
staining positive for CD4 were quantified. P-Selectin was visualized using a biotiny-
lated goat anti-rabbit secondary antibody (biotinylated goat anti-rabbit IgG, Vector
laboratories) and staining with a peroxidase kit (ABC Vectastain Elite, Vector Lab-
oratories).
2.2.8 Statistical Analysis
The data was analyzed on GraphPad Prism (version 6.07).
Experimental data is expressed as mean ±SD unless stated otherwise. Echocar-
diographic in vivo data is presented as median (25th - 75th percentile) and non-
parametric statistical tests were used. Analysis of more than two unpaired, non-
parametric sets (e.g. attachment of microbubbles to CD4+ versus CD4− cells vs.
negative control or microbubble signals within and between animal groups) were
compared using a Kruskal-Wallis ANOVA with Dunn’s post hoc test. Correlations
between 2 parameters (e.g. microbubble signal vs. CD4+ cell number in tissue) were
assessed using Spearman correlation.
A two-sided p value <0.05 was considered as statistically significant.
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2.3 Results Imaging of the acute phase
2.3.1 Scoring of Myocarditis
Severity 0
Severity 1
Severity 2
Severity 3
Severity 4
moderate
severe
Figure 2.9: Induction efficacy.
Animals developed experimental autoimmune
myocarditis that was scored positively by the
pathologist in 52% of all cases. Animals that
showed no myocarditis, were scored 0 in 48%
of all cases.
The detailed percentages for animals with de-
tected myocarditis was 13% for score 1, 22% for
score 2, 6% for score 3 and 11% for score 4.
Due to the small number of animals per group,
mice with severity degree 3 and 4 were grouped as “severe myocarditis”, severity
degrees 1 and 2 as “moderate myocarditis, while injected mice that did not develop
myocarditis were grouped with sham-injected mice as “no myocarditis”.
(a) (b) (c)
Figure 2.10: Exemplary H&E stainings for (a) no myocarditis (b) moderate myocarditis
and (c) severe myocarditis. Red markings shows the area of intense leukocyte infiltration
in the example for moderate myocarditis.
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2.3.2 In vitro assessment of microbubble CD4 interaction
Flow chamber and in vitro cell-based assays were used to characterize MBCD4 inter-
actions with CD4.
In cell-based assays, MBCtr showed no attachment to either CD4
− (0.11 ±0.06 )
or CD4+ leukocytes (0.06 ±0.05), nor did MBCD4 to CD4− cells (0.06 ±0.04). In
comparison, MBCD4 attachment to CD4
+ cells was significantly higher (p<0.001)
with an average of 0.55 ±0.06 microbubbles per cell (see Figure 2.11).
Under flow conditions in a parallel flow chamber, attachment of MBCD4 (3.8 ±3.2)
was significantly greater (p<0.001) than MBCtr (0.8 ±1.0) (see Figure 2.12).
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Figure 2.11: (a) CD4-targeted Microbubble adhesion to differential CD4 expressing cells.
Exemplary microscopy images of MBCD4 incubated with CD4
− (b) or CD4+ cells (c).
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Figure 2.12: Examples of CD4-targeted microbubbles adhering to a CD4-coated flow
chamber. First (a) and last frame (b) of a 4 second video sequence are shown. A maximum
intensity projection of 120 acquired frames over a 4 second video illustrates the slowing
and eventually firm adhesion of individual microbubbles (red arrowheads). Quantification
of adhered microbubbles was done on 120 different field of views per condition.
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2.3.3 Baseline characteristics and echocardiographic parameters
Mice with severe myocarditis were significantly lighter than both mice with no or
moderate myocarditis (see Table 2.2).
Both the heart weight (determined post-mortem) as well as the left ventricular
mass (determined by echocardiography) were higher in mice with severe myocarditis
compared to the moderate or no myocarditis groups.
E-wave velocity was lower in mice with severe myocarditis compared to the other
groups, while A-wave and the ratio E/A was not.
Table 2.2: Physiological and echocardiographic measures. Values are presented as median
(25th - 75th percentile). P-values were calculated in comparison to ”no myocarditis”. * p
<0.05; ** p <0.01; *** p <0.001.
No Myocarditis Moderate Myocarditis Severe Myocarditis
(n=20) (n=14) (n=7)
Body weight (g) 22.5 (18.6 – 24.8) 20.0 (19.4 - 22.7) 15.5 (14.9 - 16.4)**
Heart rate (bpm) 388 (349 – 490) 413 (392 - 473) 403 (351 - 461)
Heart weight (mg) 112 (105 – 126) 119 (113 - 132) 171 (147 - 207)***
LV mass (mg) 76 (65 – 90) 88 (72 - 96) 117 (82 - 137)**
LV AWd (mm) 0.9 (0.8 - 1.0) 1.0 (0.8 - 1.1) 1.4 (0.9 - 1.7)*
LV AWs (mm) 1.3 (1.2 - 1.7) 1.5 (1.2 - 1.6) 1.8 (1.3 - 2.0)
LV PWd (mm) 0.8 (0.7 - 0.9) 0.7 (0.7 - 1.0) 1.0 (0.8 - 1.1)
LV PWs (mm) 1.2 (1.0 - 1.3) 1.1 (1.0 - 1.3) 1.1 (1.0 - 1.3)
LV IDd (mm) 3.5 (3.2 - 3.7) 3.4 (3.3 - 3.7) 3.0 (2.5 - 3.5)
LV IDs (mm) 2.1 (1.5 - 2.5) 2.0 (1.9 - 2.3) 1.7 (1.6 - 2.9)
LV Vol d (μl) 52 (40 – 57) 46 (44 - 57) 38 (24 - 52)
LV Vol s (μl) 15 (7 – 22) 13 (10 - 18) 9 (7 - 27)
EF (%) 73 (61 – 83) 70 (69 - 77) 69 (42 - 76)
β (s−1) 0.8 (0.5 – 1.2) 0.6 (0.4 - 1.0) 0.7 (0.2 - 0.8)
A*β 10 (2 – 29) 18 (8 - 31) 26 (6 – 49)
E-wave (mm s−1) 613 (563 – 734) 695 (567 - 802) 527 (405 - 561)*
A-wave (mm s−1) 415 (371 – 454) 400 (346 - 531) 354 (154 - 428)
E/A 1.5 (1.3 – 1.7) 1.7 (1.3 - 1.8) 1.5 (1.0 - 2.0)
LV AWd/s left ventricular anterior wall during diastole/systole; LV PWd/s left ventric-
ular posterior wall during diastole respectively systole; LV IDd/s left ventricular internal
diameter during diastole respectively systole; LV Vold/s Left ventricular volume during di-
astole respectively systole; EF ejection fraction; β Microbubble replenishment rate; A*β
Myocardial blood flow estimate E-wave/A-wave velocity early/atrial filling velocity;
E/A early/atrial filling velocity ratio.
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Last, the anterior wall thickness during diastole in the severe myocarditis group
was significantly increased compared to no myocarditis. For all other echocardio-
graphic parameters there were no significant differences between the groups.
Of note, A*β as an estimate of myocardial blood flow was not different between
groups, albeit with large differences between individual animals.
Left ventricular strain parameters
Speckle tracking based strain measurements have been reported to be more sensitive
for the detection of global changes in left ventricular function when compared to
conventional echocardiographic measures listed above [41]. Global peak strain and
peak strain rate were assessed on left ventricular long-axis and short axis images.
In mice with severe myocarditis, radial and circumferential strain showed a trend
towards lower values while longitudinal strain was significantly decreased compared
to animals without myocarditis (p=0.009) or moderate myocarditis (p=0.005). How-
ever, strain rates did not differ between animals with severe and moderate myocardi-
tis and both strain and strain rate values were identical between mice with moderate
and mice with no myocarditis (see Figure 2.13).
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Figure 2.13: Strain imaging data according to myocarditis severity. Data is presented as
25th to 75th percentile boxplots with median and total range of values of video intensities.
P-value: * p=0.009 compared to no myocarditis.
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2.3.4 Ultrasound molecular imaging
Representative examples of color-coded intensity images for an animal without and
for one with severe myocarditis respectively are shown in figure 2.14.
The selected animal with severe myocarditis showed visibly increased signals for the
epitope-specific MBCD4, MBPSel and MBLC as well as moderate increase in control
microbubble signal.
Figure 2.14: Examples of color-coded contrast-enhanced ultrasound (CEU) molecular
images in an animal with no, moderate or severe myocarditis, respectively for microbubbles
bearing isotype control antibody (MBIso), MB bearing antibody targeting lymphocyte
CD4 (MBCD4) or endothelial P-Selectin (MBPSel) and MB with a negative electric charge
for targeting of leukocyte (MBLC)
Figure 2.15 shows the data for ultrasound molecular imaging in all three groups
of mice.
Signal enhancement was similarly low for all microbubbles in mice without my-
ocarditis. In comparison, in mice with myocarditis the signals for MBCD4, MBPSel
and MBLc were all significantly higher than signal from MBIso. Importantly, this
was not just the case in severe but also in moderate myocarditis.
In mice with severe myocarditis, an increase in signal from MBIso could be observed,
which was, however, not significant when compared to the corresponding signals in
the two other groups (p=0.99 or p=0.15 respectively).
While the absolute signal intensities for MBCD4, MBPSel and MBLc increased in se-
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vere myocarditis compared to mice with moderate myocarditis, the ratios for the
targeted versus the control microbubbles remained constant at a two to three-fold
increase due to non-significantly elevated signal from internal controls (MBIso).
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Figure 2.15: Signal enhancement from targeted microbubbles (MBCD4, MBPSel, MBLC)
compared to isotype control microbubbles (MBIso). Data is presented as 25th to 75th
percentile boxplots with median and total range of values of video intensity. P-values: *
p<0.05, ** p<0.01, *** p<0.001
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Figure 2.16: Blocking of CD4 (n=7)
with a monoclonal antibody (H129.19)
abolishes signal from MBCD4 com-
pared to animals without the treatment
(n=20).
Signal for MBCD4 was abolished after
blocking with anti-CD4 antibody as demon-
strated in 7 additional animals (see Fig-
ure 2.16). The reduction was significant
(p=0.03) when compared to signals for
MBCD4 of animals without treatment with
the blocking antibody prior to imaging.
Correlation analysis of CD4+ leukocyte
counts in myocardia sections with molecu-
lar imaging data showed a signal correlation,
albeit modestly, with MBCD4, MBPSel and
MBLc (Figure 2.17).
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Figure 2.17: (a) Correlation of contrast-enhanced ultrasound molecular imaging data
for MBIso, MBCD4, MBPSel and MBLC in respect to number of CD4
+ cells per mm2 in
corresponding tissue sections. (b) Examples of low-level and extensive myocardial CD4+
leukocyte infiltration.
To assess whether a measured parameter is a diagnostic test for myocarditis,
receiver-operating-characteristic (ROC) curves have been calculated for selected pa-
rameters (see figure 2.18). The accuracy of a test is determined by how well the
parameter can distinguish the animals into groups with or without myocarditis.
The area under the curve was determined and values > 0.80, 0.7 − 0.79 or < 0.69
were considered as good, fair or poor tests, respectively.
A fair diagnostic parameter for myocarditis was found to be heart-weight (area=0.77)
and bodyweight (area=0.73) while left ventricular mass (area=0.67) was ranked as
poor. Most importantly, signals in molecular imaging from MBCD4, MBPSel and
MBLC showed a good ability to predict myocarditis (area> 0.8). The ROCs for
MBIso, ejection fraction, wall thicknesses and strain measurements did not show a
predictive value for acute myocarditis.
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Figure 2.18: Receiver-operating-characteristic (ROC) curves in diagnosing myocarditis
shown for selected parameters. Data presented is area under curve with respective p values
(n=20 mice without myocarditis, n=21 mice with myocarditis).
(a) Ejection fraction (area=0.54, p=0.63); (b) Strain longitudinal (area=0.56, p=0.51);
(c) Heartweight (area=0.77, p=0.02); (d) Bodyweight (area=0.73, p=0.03); (e) Left
ventricular mass (area=0.67, p=0.05); (f) Signal for MBIso (area=0.54, p=0.62); (g)
Signal for MBCD4 (area=0.86, p<0.001); (h) Signal for MBPSel (area=0.90, p<0.001); (i)
Signal for MBLC (area=0.81, p<0.001)
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2.4 Discussion
Myocarditis and the ensuing inflammatory autoimmune phenomena can lead to
chronic dilated cardiomyopathy and heart failure. Currently available non-invasive
imaging methods detect the functional or structural consequences of infection or in-
flammation such as tissue necrosis or edema and are limited in diagnostic accuracy.
Therefore, the use of contrast enhanced ultrasound molecular imaging to detect the
inflammatory process in myocarditis was investigated. The obtained results indi-
cate that (1) CEU ultrasound molecular imaging detects myocardial inflammatory
infiltration and endothelial cell activation independent of functional consequences
in autoimmune myocarditis, and (2) CEU molecular imaging allows for the detec-
tion of CD4+ lymphocytes which contribute to the pathogenesis of myocarditis and
dilated cardiomyopathy.
CEU molecular imaging detects myocarditis independent of
functional impairment.
Despite advances in non-invasive imaging, myocarditis continues to represent a chal-
lenging diagnosis. While conventional echocardiography can detect structural and
functional alterations in fulminant myocarditis [43], it is limited in sensitivity and
specificity in lower grade acute myocarditis, which has a higher likelihood of pro-
gression to dilated cardiomyopathy.
In this study, left ventricular mass and heart-weight was found to be increased while
left ventricular function (E-wave velocity, longitudinal strain) tended to be decreased
in the group with severe myocarditis. An increase in anterior wall thickness both
in systole and diastole was observed and does fall in line with the increase in heart-
mass in respect of the peaking inflammatory processes. However, despite the use
of high-resolution ultrasound and highly sensitive speckle tracking analysis, there
were no differences in left ventricular size and function between the group without
myocarditis and the group with only moderate myocarditis.
Direct assessment of the inflammatory process - responsible not only for acute my-
ocarditis, but also for the progression to dilated cardiomyopathy through autoim-
mune mechanisms - may improve the diagnostic performance of cardiac ultrasound.
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This study shows that CEU molecular imaging with microbubbles targeted to leuko-
cytes and P-Selectin yields increased signal not only in the group with severe my-
ocarditis, but also in the group with moderate myocarditis, suggesting that the direct
detection of the inflammatory infiltrate rather than its functional consequences re-
sults in better sensitivity in detecting myocarditis.
In addition to relatively non-specific targeting of activated leukocytes using neg-
atively charged microbubbles [38], antibody-targeting of microbubbles toward the
endothelial cell adhesion molecule P-Selectin was applied. P-Selectin is expressed
on the surface of the vascular endothelium upon inflammatory stimulation. In
myocarditis, P-Selectin plays an important role by mediating the recruitment of
pathogenic T-cells into the myocardial tissue [44]. The obtained results are in
line with earlier reports, which show that CEU molecular imaging can detect car-
diac transplant rejection by targeting activated leukocytes or inter-cellular adhesion
molecule-1 [45, 46]. However, while the inflammatory process in transplant rejection
shares certain similarities with myocarditis, an important difference that complicate
the diagnostic challenges is the low-grade and focal nature of the inflammatory in-
filtrate in moderate myocarditis. Also, the finding that CEU molecular signal for
both leukocyte- and P-Selectin targeted microbubbles was much greater in severe
compared to moderate myocarditis indicates that various degrees of disease activity
can be discerned.
CEU molecular imaging assesses the infiltration with pathogenic
CD4+ lymphocytes
In animal models of both viral and autoimmune myocarditis, CD4+ lymphocytes
represent a relatively small subset of leukocytes infiltrating the myocardium [47].
However, development of myocarditis upon transfer of appropriately activated CD4+
lymphocytes in host animals suggests a decisive role of CD4+ lymphocytes in my-
ocarditis [35]. In addition, the number of CD4+ lymphocytes within tissue correlates
with cardiac functional impairment in the chronic stage of experimental autoimmune
myocarditis [48]. Therefore, a novel, CD4+-targeted microbubble using was devel-
oped and validated. Flow chamber assays and in vitro experiments showed that this
targeting ligand displayed on the microbubble surface mediates specific attachment
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to CD4+ lymphocytes, and that attachment occurs also under flow conditions.
In vivo, CEU molecular imaging showed increased signals both in moderate and
in severe myocarditis, and the signal correlated with the numbers of CD4+ lym-
phocytes present in tissue. While direct observation of microbubble-lymphocyte
interactions in vivo was not possible, abolishment of signal by blocking of CD4+
indicates selective targeting similar to in vitro observations.
Limitations of this study.
There are several limitations of this study that deserve attention. The used model of
experimental autoimmune myocarditis was induced with peptide-based self-antigens
rather than by virus-induction. However, EAM shares many patho-physiological fea-
tures with virus-induced myocarditis, and has been used extensively to study the
autoimmune processes caused by initial viral myocyte infection [49].
Regarding CEU molecular imaging, differences in myocardial perfusion between
groups could potentially influence the results. While there was a high variability
in myocardial perfusion in mice with severe myocarditis, we did not find significant
differences between groups, and in particular perfusion was identical in mice without
and mice with moderate myocarditis. In addition, the low signals for control mi-
crobubbles in both groups with myocarditis argue against an influence of myocardial
flow on CEU molecular imaging results.
Last, the limited spatial resolution of CEU at 7MHz in the mouse model that was
used precluded a regional assessment of disease activity, which would be desirable
for example for the guidance of endomyocardial biopsies in patients.
2.5 Summary
In summary, the results of this study indicate that CEU molecular imaging can be
used to detect the inflammatory process in myocarditis and discriminate the disease
severity independent of cardiac function.
In addition, specific molecular imaging of a leukocyte subset that is driving the
autoimmune process in myocarditis is possible.
As a consequence, CEU molecular imaging can potentially be useful in the diagnosis
of myocarditis.
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3 Contrast imaging for the
prediction of long-term
consequences of acute myocarditis
3.1 Introduction
The inflammatory processes in myocarditis have been described in chapter 2.1.1.
The natural course of myocarditis is spontaneous recovery in 40-60% of biopsy-
proven cases [50] without any impact on heart function. However, at least a fifth of
patients diagnosed with myocarditis progress to dilated cardiomyopathy with my-
ocardial remodeling that results in ventricular dysfunctions [51]. The long-term
prognosis for patients developing reduced ejection fraction is unfavorable with mor-
tality rates of more than 50 % after 4 years [52], and only a third of patients report
partial or complete recovery [53] of left ventricular function. Clinically, dilated
cardiomyopathy with reduced ejection fraction manifests with symptoms of heart
failure (eg. dyspnea, decreased exercise tolerance). In addition, dilated cardiomy-
opathy with reduced ejection fraction represents arrhythmogenic substrate [54] and
entails the risk for sudden cardiac death. While the numbers are not dramatically
high, disease progression can be dramatic and myocarditis is responsible for 10% of
heart transplantations worldwide [55].
The change in myocardial tissue composition is the driving force for ventricular di-
latation and decrease of heart function. The main components in the myocardial
extracellular matrix are fibrillar collagens of type I (>60%) and type III (10-40%)
and to a lesser extend type V (<5%) and other elements (laminins, proteoglycans
etc.) [56]. The collagen network in the myocardium can be divided into 3 separate
components and their organization is important for the maintenance of myocardial
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compliance: (1) the endomysial collagen surrounds individual myocytes and inter-
connects them by struts, (2) the perimysal collagen surrounds groups of myocytes
and (3) the epimysial collagen surrounds entire muscle bundles in the myocardium.
Upon cardiomyocyte damage, either by direct injury or by an uncontrolled host
immune response, the myocytes damage will be cleared. The turnover rates of car-
diomyocytes are very low at 0.5% to 1% of total cardiac cells per year [57] and the
regenerative capacity of the myocardium is very limited. Resident cardio-fibroblasts
will replace damaged myocytes with extracellular matrix, mainly collagen type I. In
humans, the global collagen ratio of typI/typeIII increases in dilated cardiomyopa-
thy from 0.6 to 1.3 [58]. Less collagen type III leads to a reduction of the elastic
properties of the myocardium and impacts the diastolic function. In addition, a
decrease in interchain cross-linking results in myocyte sliding and thus contributes
to chamber dilatation [59].
Important players in the degradation of existing myocardium that is subsequently
replaced with extracellular proteins are proteases. The proteases can originate from
infecting viruses. However, the most important source of proteases are myocar-
dial cells. Upon stimulation by pro-inflammatory cytokines, endothelial cells, fi-
broblasts and cardiomyocytes secrete a set of proteases (matrix metalloproteinases
(MMPs), thrombin, elastase). In infarction models, cytokines like IL-1, IL-6 and
TNF-α induce proteases (e.g. MMP-2, thrombin) [60]. Higher MMP activity in-
creases trans-endothelial migration of leukocytes (see figure 3.1). The invading neu-
trophils and macrophages secret a different set of proteases, including MMP8, MMP9
and MMP12 as well as elastase, cathepsin G that augment leukocyte recruitment
and initiate a vicious cycle.
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Figure 3.1: Proteases in Dilated cardiomyopathy. (A) MMPs are responsible for degrad-
ing the basement membrane and increase transendothelial migration of immune-cells. (B)
Cardiac cells (macrophages, cardiomyocytes, dendritic cells, endothelial cells, fibroblasts)
get activated and secrete chemokines. Activated MMPs cleave these chemokines, modu-
lating their activity and gradients (activation or inactivation). (C) Secreted cytokines get
processed by MMPs as well and change their activity, contributing to an exacerbation or
resolution of the inflammation. (E) MMP up-regulation leads to cleavage of ECM compo-
nents, myocardial slippage and a change in the normal ventricular structure and function.
Adopted from Westermann et al. [61].
CCL, CC-chemokine ligand; CCR, CC-chemokine receptor; MMP, matrix metallopro-
teinase; IL, interleukin; IFN, interferon; TNF, tumor necrosis factor; DC, dendritic cell;
ECM, extracellular matrix.
Beside the effect of vascular permeability and degradation of extracellular-components
(predominantly collagens), the activated proteases can cleave specific chemokines
and cytokines and thus modulate their properties. The proteolytic cleavage is a
natural way to clear pro-inflammatory cytokines (e.g. CCL7 is cleaved by MMP2).
However, IL-1β and IFN-β for example are degraded by MMP9, while latent TNF-
α that is bound to ECM gets activated through cleavage and subsequent release
by MMPs[62, 63], both processes that increase inflammation and drive the car-
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diac remodeling. Another effect of increased protease activity is the activation of
protease-activated receptors (PAR). PAR-1, 2 and 4 are expressed on endothelial
cells, cardiomyocytes and cardiac fibroblasts [64] and are involved in sensing condi-
tions of the extracellular matrix. PAR-1 is especially important in heart remodeling
while PAR-2 is associated with the inflammatory processes. The receptors are in-
dividually activated by a different set of specific MMPs, thombin, elastase, and
coagulation proteases.
Upon activation, PAR-1 trans-activates the epidermal growth-factor receptor and
stimulates multiple signaling pathways (via ERK, p38, AKT) [65] that lead to in-
creased proliferation of cardiac fibroblasts and an increase in cytokine expression.
The expression of IFN-β and CXCL10 is upregulated as well [66]. Both increase NK
cell recruitment and fuel the inflammatory processes in myocarditis. PAR-2 and -4
is expressed on myocardial cells, neutrophils, mast cells and other leukocytes and
strongly increase chemotaxis [67] and the release of inflammatory mediators [68].
IL-1β expression correlates with fibrotic lesions and heart weight in the chronic phase
of myocarditis [20]. IL-6 neutralization increases myocardial fibrosis in cardiac graft
models [69], suggesting a pivotal role in the development of DCM. IL-17A deficient
mice show reduced gene transcription of various MMPs and are protected from
post-myocarditis remodeling [70]. Additionally IL-1, IL-6 and IL-17 induce MMP
secretion in myocardial fibroblast and myocytes suggesting a pivotal role in matrix
remodeling [71] that leads to the progression of DCM.
Together, the changes in the extracellular matrix and the decrease of myocytes
numbers lead to dilated cardiomyopathy with cavity enlargement of left and/or right
ventricle with an reduced ejection fraction. Defined thresholds of an ejection frac-
tion <45% and left ventricular end-diastolic diameter >112% in humans [72] are
considered diagnostically relevant.
The described changes that occur at the cellular level have a impact on the function
of the myocardium. The heart action can be simplified as a periodic contraction
during systole and relaxation during diastole with the goal of pumping blood into
the body (see figure 3.2). During systole, the myocytes shorten and this force is
sustained and distributed by the ECM and thus the cavity volume decreases. In
this process Spiraling arrangement of muscle fibers in the myocardium contribute
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to the augmentation of a 15-20% shortening of myofibers into an ejection fraction of
around 60% [73]. During diastole, relaxation of the myocytes in combination with
the elastic properties of the ECM allows the cavity to fill again.
Any changes in either the complex system of myocardial muscle-fibers or the com-
position of the ECM leads to reduced forces that can be generated against the
volume-load of the heart, and lead to chamber dilatation and reduced systolic func-
tion.
Heart
chamber
Parallel elastic
Serial elastic
Contractile
(a) (b)
Figure 3.2: (a) Simplified model of longitudinal heart forces, generated by contractile
muscles and sustained by extracellular matrix network. After Fry et al. [74] (b) Schematic
of spiraling heart fibers in the left ventricle. Adapted from ”The Dynamic Heart and
Circulation” [75]
Aims of the study
Clinically used imaging techniques such as echocardiography or CMR enable the
assessment of the functional consequences of myocarditis. However, there is no
imaging technique available, that offers robust prognostic information during the
inflammatory process that predicts the cardiac remodeling and development of di-
lated cardiomyopathy. Therefore the aim of the study was to assess the prognostic
value of ultrasound molecular imaging of myocardial inflammation during the acute
phase of myocarditis for late changes in the chronic phase.
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3.2 Material & Methods
3.2.1 Study design and animal model
All experiments were performed in accordance with Swiss Federal Legislation and
were approved by the Animal Care Committee of the Canton of Basel. A total of
54 female BALB/c mice were used for this study.
Imaging of the acute phase (Time point 1, T1) in Myocarditis. In 54 mice,
experimental autoimmune myocarditis (EAM) was induced as described (see chapter
2.2.1). On day 21 after induction, the following imaging datasets were acquired:
Day 21 imaging during acute phase
• high resolution transthoracic echocardiography,
• speckle tracking strain imaging,
• CEU molecular imaging for leukocytes, P-Selectin and CD4+ lymphocytes.
Imaging of the chronic phase (Time point 2, T2) The animals were then recov-
ered and imaging was again performed during the chronic phase during myocarditis
to assess the potential predictive value of molecular imaging for late changes. Anal-
ysis at this second time point at 63 days post induction included:
Day 63 long term imaging
• high resolution transthoracic echocardiography,
• speckle tracking strain imaging,
• invasive left ventricular pressure measurements.
Histology of the hearts at the mid-ventricular level was performed for the assessment
of myocardial fibrosis.
3.2.2 Microbubble Preparation
Perfluorocarbon-filled, lipid-shelled microbubbles were prepared by sonification of
a gas-saturated aqueous suspension of distearoyl-phosphatidylcholine (2 mg/ml;
Avanti Polar Lipids, Alabaster AL, USA) and polyoxyethylene-(40)-stearate (1 mg/ml;
Sigma-Aldrich, Buchs). These non-targeted microbubbles were used for the assess-
ment of myocardial perfusion. Microbubbles for targeting of leukocytes (MBLc) were
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Figure 3.3: Study design. Animals were challenged with 2 injections containing cardiac
α-myosin peptide and analyzed 3 weeks after induction of experimental autoimmune my-
ocarditis. Mice were imaged again on day 63 post-induction and sacrificed only then for
tissue collection.
prepared by adding distearoyl-phosphatidylserine (0.3 mg/ml; Avanti Polar Lipids)
to the aqueous suspension before sonification [38].
For targeting of P-Selectin and CD4, distearoyl-phosphatidylethanolamine-
PEG(3400)-biotin (0.14 mg/ml; Creative PEG Works, Chapel Hill, NC, USA) was
added to the lipid suspension. Microbubbles targeted to P-Selectin (MBPSel) and
to CD4 (MBCD4) were then prepared by conjugation of biotinylated anti-P-Selectin
antibody (RB40.34, BD Bioscience) or anti-CD4 antibody (H129.19, BD Bioscience)
to the microbubble surface using biotin-streptavidin-biotin linking as previously de-
scribed [39]. Control microbubbles (MBIso) bearing a non-specific isotype control
antibody (R3-34, BD Bioscience) were also prepared. Microbubble concentration
and size were measured by electro-zone sensing (Multisizer III, Beckman-Coulter).
3.2.3 Animal instrumentation
On day 21 and day 63 post-immunization respectively, the mice were anesthetized
as described (see chapter 2.2.4)
For microbubble injections on day 21, the right internal jugular vein was cannulated
with 0.97 mm polyethylene tubing (PE-50, BD Diagnostics). The animals were
transferred onto a temperature-regulated imaging stage (Vevo Imaging Station).
After the imaging procedure, the tube was removed and the right jugular vein lig-
ated. The skin was sutured using a 6-0 mono-filament thread (Prolene, Ethicon,
New Jersey). The animals were recovered from anesthesia and after regaining con-
sciousness were treated with 0.1 mg/kg bodyweight buprenorphine s.c. (Temgesic,
Schering-Plough, New Jersey) every 8 hours.
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3.2.4 Echocardiography
High frequency (40MHz, MS 550D transducer) ultrasound imaging (Vevo 2100, Vi-
sualSonics Inc., Toronto, Canada) was performed for assessment of cardiac structure
and function on both imaging time points T1 and T2.
M-Mode images of the left ventricle at the height of the papillary muscles were used
to measure anterior and posterior wall thickness, left ventricular end-diastolic diam-
eter (LVEDD) and left ventricular end-systolic diameter (LVESD). Left ventricular
ejection fraction (EF) and left ventricular mass were derived from these measure-
ments as described previously [40].
E-wave and A-wave velocity were measured using pulsed wave Doppler tracings from
a modified apical 4-chamber view to assess flow across the mitral valve.
Para-sternal long- and short-axis B-mode images were acquired at a frame rate of
>200 frames per second. Longitudinal, radial and circumferential global peak strain
values were derived from the B-mode images using a speckle tracking algorithm
(VevoStrain, VisualSonics) [41]. Briefly, cine-loops with two cardiac cycles not dis-
torted by respiratory movements were selected and the endocardial and epicardial
borders were traced on end-diastolic frames. After automated tracing, manual ad-
justments were made as necessary for good tracking throughout the cardiac cycles.
The strain measurements were then averaged over the two cardiac cycles without
the use of temporal smoothing filters.
3.2.5 Contrast Enhanced Ultrasound molecular Imaging
Contrast ultrasound imaging (Sequoia Acuson C512; Siemens Medical Systems USA
Inc., Mountain View, CA) was performed with a high-frequency linear-array probe
(15L8) held in place by a railed gantry system. The left ventricle was imaged in
short axis at the papillary muscle level from a left parasternal window. ECG-gated
triggering was used to acquire end-systolic frames. For the detection of the contrast
agent, power modulation and pulse inversion (Contrast Pulse Sequence) imaging at
a centerline frequency of 7 MHz and a dynamic range of 50 dB was used.
The gain settings were adjusted to levels just below visible noise speckle and held
constant. MBCtr, MBLc, MBPSel, or MBCD4 (3×106 microbubbles per injection) were
injected intravenously in random order. Ultrasound imaging was paused from the
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time of injection until eight minutes later when imaging was resumed at a mechanical
index of 0.87. The first acquired image frame was used to derive the total amount of
microbubbles present within the left ventricular myocardium (see Figure ??). The
microbubbles in the ultrasound beam were then destroyed with several (>10) high
intensity image frames with a mechanical index of 1.9. Several image frames at a
long pulsing interval (every 9 heartbeats) were subsequently acquired to measure
signal attributable to freely circulating microbubbles. After log-linear conversion
using known dynamic range lookup tables, frames representing freely circulating
microbubbles were digitally subtracted from the first image to derive signal from
attached microbubbles alone. Contrast intensity was measured from a region of
interest encompassing the whole left ventricular myocardium. The selection of the
region of interest was guided by fundamental frequency anatomic images of the left
ventricle acquired at 14 MHz at the end of each individual imaging sequence.
At 63 days post-induction of myocarditis, the mice were not able to hemodynamically
tolerate multiple fluid injections. Therefore, we abstained from performing perfusion
imaging. In addition, it was not possible to perform ultrasound molecular imaging
for all microbubble species in all animals. Thus, ultrasound molecular imaging data
were acquired for 31 animals for MBCD4, for 10 animals for MBPSel, whereas data
for MBCtr and MBLc were acquired for all animals.
3.2.6 Left ventricular pressure measurements
After high frequency echocardiographic assessments, mice were kept anesthetized
(2% isoflurane) and transfered to a heating pad. The left internal carotid artery was
surgically exposed. A 0.3 mm diameter manometer tipped catheter (PVR-1035,
Millar, Oxford, England) was inserted through a small incision in the artery. The
catheter was then carefully advanced through the aortic valve into the left ventricle
(see figure).
Pressure parameters were recorded and analyzed with a MPVS System (AD Instru-
ments, Dunedin, New Zealand).
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Figure 3.4: Schematic representation of the heart cycle. (a) Ventricular systole and di-
astole define the two major phases in the heart cycle. (b) Wiggers diagram of the heart
cycle. Measured were left ventricular end systolic and end diastolic pressure respectively,
maximal rate of left ventricular pressure rise and decrease respectively as well as the max-
imal aortic pressure.
LVPmax: Maximal left ventricular pressure; LVPmin: Minimal left ventricular pressure;
LVPES: Left ventricular end systolic pressure; LVPED: Left ventricular end diastolic pres-
sure; dP/dTmax: Maximal rate of left ventricular pressure rise; dP/dTmin: Maximal rate
of left ventricular pressure decrease.
3.2.7 Histology
Collagen quantification in the myocardium was performed on short axis cross-sections
of the hearts of animals that were sacrificed on day 63 post-induction of myocardi-
tis. Heart tissue was fixed in 4% formaldehyde-solution and 5 μm thin sections were
prepared using a water-slide microtome (HM 340E, Zeiss, Jena). The sections were
stained with PicroSirius Red and counter-stained with hematoxyline. Full-spectrum
RGB images of the stained myocardiums were recorded. The red channel was con-
verted into a binary image using thresholding and the number of pixel above the
threshold was averaged for 3 sections per individual animal. The area signal above
the threshold in the left ventricular myocardium was normalized to the total tissue
area and presented as a percentage value.
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(a) (b) (c)
Figure 3.5: Fibrosis quantification. Red pixels display over-, blue underexposed pixels.
The fibrosis score in this example was 7.2%. (a) original RGB image. (b) Binary image to
retrieve total left-ventricular tissue area. (c) Binary image with threshold set to retrieve
the collagen-positive area (red).
3.2.8 Statistical Analysis
The data was analyzed on GraphPad Prism (version 6.07).
Experimental data is expressed as mean ±SD unless stated otherwise. Echocardio-
graphic in vivo data is presented as median (25th - 75th percentile) and preferential
non-parametric statistical tests were used due to the distributions’ non-Gaussian
nature, small sample sizes and/or unresolvable outliers. Comparisons between two
unpaired, non-parametric data sets were made using a Mann-Whitney rank sum
test. Analysis of more than two unpaired, non-parametric sets were compared using
a Kruskal-Wallis ANOVA with Dunn’s post hoc test. Comparison between paired
datasets (e.g. functional echocardiography at two different time points per animal)
was done using a Wilcoxon matched-pair rank test. Correlations between 2 param-
eters (e.g. Fibrosis score vs. functional parameters) were assessed using Spearman
correlation.
A two-sided p value <0.05 was considered as statistically significant.
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3.3 Results Imaging of the chronic phase
3.3.1 Physiological parameters and structural and functional
ultrasound imaging during the acute (T1) and chronic
phase (T2) of myocarditis
Table 3.1 shows physiological parameters and ultrasound imaging data for struc-
tural and functional parameters assessed both during the acute phase (T1, 21 days
post-induction) and the chronic phase (T2, 63 days post-induction) of myocarditis.
The physiological parameters included bodyweight and heart rate. Bodyweight
increased significantly between time points T1 and T2, whereas heart rate was sig-
nificantly decreased at time point T2.
Physical heart weight was assessed only at time point T2.
The dimensions of left ventricular anterior wall (LVAW) as well as posterior wall
(LVPW) thicknesses decreased significantly between the two time-points (see Figure
3.6). In contrast, the left ventricular internal diameter (LVID) and subsequently the
left ventricular volume increased both during diastole and systole.
(a) (b) (c)
Figure 3.6: Dimensions of (a) left ventricular anterior wall, (b) posterior wall and (c)
internal diameter for both time points T1 (acute phase) and T2 (chronic phase). Presented
data is plotted as scatter with median.
For systolic functional parameters, the ejection fraction showed a significant de-
crease at time point T2.
Global strain and strain rates decreased overall for radial, circular and longitudinal
stain (see Figure 3.7 and Table 3.1).
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Table 3.1: Comparisons of functional parameters measured during acute (T1) and chronic
phase (T2) of myocarditis. Data is presented as median (25th - 75th percentile).
Acute Phase (T1) Chronic Phase (T2) p-values
Physiological parameters
Bodyweight (g) 21.1 (19.2 – 21.6) 22.7 (21.9 – 23.6) <0.001
Heart rate (bpm) 421 (391 – 452) 364 (345 – 389) <0.001
Heart weight (mg) n/a 133 (127 – 144) n/a
Echocardiographic parameters of LV structure
LV Mass (mg) 84 (76 – 94) 86 (77 – 93) n.s.
LV AWd (mm) 0.91 (0.83 – 1.06) 0.85 (0.77 – 0.96) <0.01
LV AWs (mm) 1.37 (1.23 – 1.51) 1.15 (1.04 – 1.26) <0.001
LV PWd (mm) 0.75 (0.71 – 0.90) 0.68 (0.63 – 0.72) <0.001
LV PWs (mm) 1.19 (1.07 – 1.39) 0.93 (0.84 – 1.00) <0.001
LV IDd (mm) 3.50 (3.20 – 3.73) 3.90 (3.84 – 4.02) <0.001
LV IDs (mm) 2.10 (1.78 – 2.42) 2.87 (2.76 – 3.16) <0.001
LV Vold (μl) 51 (41 – 59) 66 (60 – 71) <0.001
LV Vols (μl) 14 (10 – 21) 32 (28 – 40) <0.001
Echocardiographic parameters of LV systolic function
Ejection fraction (%) 71 (65 – 78) 51 (44 – 56) <0.001
Strainrad (%) 33 (25 – 42) 24 (19 – 27) <0.001
Straincirc (%) -18 (-22 – -16) -13 (-15 – -10) <0.001
Strainlong (%) 8.7 (7.4 – 10.2) 6.9 (5.8 – 8.0) <0.01
Strainraterad (s
−1) -7.6 (-8.4 – -6.1) -4.5 (-5.1 – -3.4) <0.001
Strainratecirc (s
−1) -13 (-15 – -11) -11 (-12 – -10) <0.001
Strainratelong (s
−1) -5.6 (-6.8 – -5.1) -4.4 (-4.7 – -3.7) <0.001
Echocardiographic parameters of LV diastolic function
E-wave velocity (mm s−1) 668 (586 – 744) 652 (559 – 811) n.s.
A-wave velocity (mm s−1) 306 (178 – 359) 149 (51 – 209) <0.001
E/A 1.9 (1.6 – 2.1) 4.0 (2.8 – 6.0) <0.001
LV Mass Left ventricular mass; LV AWx Left ventricular anterior wall during diastole or
systole respectively; LV PWx Left ventricular posterior wall during diastole or systole respectively;
LV IDx Left ventricular internal diameter during diastole or systole respectively; LV Volx Left
ventricular volume during diastole or systole respectively; Strain Radial. circular or longitudinal
strain respectively; E-wave early filling wave; A-wave atrial filling wave; E/A early/atrial filling
velocity ratio
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(a) (b)
(c)
Figure 3.7: Strain data of both time points T1 and T2 for (a) radial strain, (b) cir-
cumferential strain and (c) longitudinal strain. Presented data is plotted with horizontal
median.
Regarding diastolic indices, the E/A ratio was significantly increased (median of
1.9 for T1 vs. 4.0 for T2. see Figure 3.8) due to an increase in A-wave velocity
(median of 306 mm/s vs. 149 mm/s) while E-wave velocities remained unchanged.
Of note, the spread of E-velocities and thus E/A ratio was larger at T2 than at T1
potentially due to the different degrees of myocardial damage.
T2T1
Figure 3.8: Spread of E/A ratios at time points T1 and T2.
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3.3.2 Tissue fibrosis during the chronic phase (T2)
Quantification of collagen-rich areas in PicroSirus-stained heart sections of 54 in-
dividual animals showed values ranging from 0.3% to 8.4% of the total myocardial
area (Figure 3.9)
The extent of fibrosis did not show any correlation to the total myocardial area
of the left ventricle.
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Figure 3.9: (a) Exemplary histology for an animal with low or high fibrotic area respec-
tively. (b) Sorted plot of all scored animals. (c) Correlation of myocardial area against
fibrotic area.
3.3.2.1 Correlation of functional parameters during T1 with tissue fibrosis
during T2
Regression analysis was performed to assess whether functional parameters acquired
during the acute phase of myocarditis (T1) are able to predict structural changes that
occur during the chronic phase (T2) of myocarditis. The results of this regression
analysis are presented in Table 3.2.
Significant but weak correlations to the extent of fibrosis were found for heart
rate, left ventricular mass and the left ventricular posterior wall with higher values
being predictive of more fibrosis.
67
Table 3.2: Correlation analysis of functional parameters measured during the acute phase
(T1) of myocarditis with the fibrosis score at the chronic phase (T2). Data presented are
nonparametric Spearman coefficients (rs) and respective two-tailed p values.
vs. Fibrosis (T2)
rs p-value
Physiological parameters
Bodyweight (g) −0.09 0.51
Heartrate (bpm) 0.28 0.042*
Echocardiographic parameters of LV structure
LV Mass (mg) 0.32 0.019*
LV AWd (mm) 0.10 0.47
LV AWs (mm) 0.01 0.92
LV PWd (mm) 0.32 0.020*
LV PWs (mm) 0.17 0.23
LV IDd (mm) 0.03 0.84
LV IDs (mm) 0.16 0.24
LV Vold (μl) 0.04 0.80
LV Vols (μl) 0.16 0.24
Echocardiographic parameters of LV systolic function
Ejection Fraction (%) −0.22 0.10
Strainrad (%) −0.16 0.25
Straincirc (%) 0.22 0.11
Strainlong (%) 0.24 0.09
Strainraterad (s
−1) −0.18 0.20
Strainratecirc (s
−1) 0.24 0.09
Strainratelong (s
−1) −0.02 0.88
Echocardiographic parameters of LV diastolic function
E-wave velocity (mm s−1) −0.08 0.55
A-wave velocity (mm s−1) −0.16 0.25
E/A 0.12 0.40
LV Mass Left ventricular mass; LV AWx Left ventricular anterior wall during diastole or
systole respectively; LV PWx Left ventricular posterior wall during diastole or systole respectively;
LV IDx Left ventricular internal diameter during diastole or systole respectively; LV Volx Left
ventricular volume during diastole or systole respectively; Strain Radial. circular or longitudinal
strain respectively; E-wave early filling wave; A-wave atrial filling wave; E/A early/atrial filling
velocity ratio
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3.3.2.2 Correlation of ultrasound molecular imaging during T1 with tissue
fibrosis during T2
A second regression analysis was performed to assess whether molecular imaging
data acquired during the acute phase of myocarditis (T1) is able to predict structural
changes that occur during the chronic phase (T2) of myocarditis.
The results showed a positive correlation with tissue fibrosis for control microbub-
bles (MBIso), microbubbles targeted to CD4 (MBCD4) and microbubbles targeted to
activated leukocytes (MBLc) with the largest correlation coefficient for MBCD4 (see
Figure 3.10).
While the results for microbubbles targeted to P-Selectin (MBPSel) showed a
higher correlation coefficient with fibrosis, this was not significant due to the low
number of animals that received MBPSel.
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Figure 3.10: Correlation fibrosis vs. signal from (a) isotype control microbubbles MBIso,
(b) CD4-targeted microbubbles MBCD4, (c) P-Selectin-targeted microbubbles MBPSel and
(d) microbubbles targeted to activated leukocytes MBLc.
69
3.3.3 Invasive hemodynamic measurements during the chronic
phase (T2)
Results of invasive hemodynamic measurements are shown in Table 3.3. In com-
parison to published values of healthy mice under isoflurane anesthesia [76], the
pressure at end of the systole was slightly reduced while the end-diastolic pressure
was significantly increased.
The maximal peak rate of pressure rise (dP/dtmax) as well as pressure decline
(dP/dtmin) were both decreased and in contrast, the left ventricular relaxation con-
stant Tau was increased.
Table 3.3: Invasive hemodynamic measurements during the chronic phase (T2) of my-
ocarditis and their published normal range in healthy mice anesthetized with isoflurane.
Experimental data is presented as median (25th - 75th percentile).
Chronic phase (T2) Published values [76]
Change vs.
normal
Pes (mmHg) 89 (83 – 92) 92 – 118 –
Ped (mmHg) 12.5 ( 8.2 – 17.0) 1 – 6 ++
dP/dtmax (mmHg s
−1) 6597 (5518 – 7245) 7700 – 14480 – –
-dP/dtmin (mmHg s
−1) 5987 (6968 – 5102) 6900 – 10400 – –
Tau (ms) 12.4 ( 9.6 – 14.3) 4.4 – 7.6 ++
APmax (mmHg) 90 (86 – 93) n.a. n.a.
Pes/ed end systolic / diastolic pressure; dP/dt maximal/minimal rate of pressure generation;
Tau Isovolumic relaxation constant; APmax/min Maximal/minimal aortic pressure
70
3.3.3.1 Correlation of functional parameters during T1 with hemodynamic
measurements during T2
Regression analysis was performed to assess whether functional parameters acquired
during the acute phase of myocarditis (T1) are able to predict changes of hemody-
namic parameters. In Table 3.4, correlations for end-systolic pressure (Pes), end-
diastolic pressure (Ped) and the maximal rate of pressure change (dP/dtmax) are
shown.
Significant, but weak correlations to the increase in Pes was found for the heart
rate.
The dimensions of the left ventricular posterior wall during systole was correlated
to end-systolic pressure with thinner wall dimensions predicting a lower Pes. The left
ventricular internal diameter showed an inverse correlation to end-systolic pressure,
with a larger internal diameter (both in diastole and systole) predicting a lower Pes.
A greater left ventricular volume (both in diastole as well as systole) correlated with
a lower end-systolic pressure as well.
The ejection fraction showed a correlation to end-systolic pressure with low values
predicting a lower Pes.
Ratio of E to A-wave velocity showed a trend but a significant correlation was
found only for the A-wave velocity with higher velocities predicting a higher end-
systolic pressure.
However, an increase or decrease in end-diastolic pressure (Ped) was not predicted
by any of the assessed functional parameters except E-wave velocity, with lower ve-
locity values indicating a higher end-diastolic pressure.
The maximal left ventricle pressure rise (dP/dtmax) showed a positive correlation
to heart rate.
Ventricular dimensions showed a general trend similar to the results for Pes. How-
ever, significant correlations were only observed for internal diameter and ventricular
volume during systole.
The ejection fraction showed a positive correlation as did E- and A-wave velocities.
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Table 3.4: Correlation analysis of functional parameters measured during the acute phase
(T1) of myocarditis with hemodynamic measurements at the chronic phase (T2). Data
presented are nonparametric Spearman coefficients (rs) and respective two-tailed p values.
vs. Pes (T2) vs. Ped (T2) vs.
dP
dtmax
(T2)
rs p-value rs p-value rs p-value
Physiological parameters
Bodyweight (g) 0.07 0.60 −0.19 0.18 0.14 0.33
Heartrate (bpm) 0.35 0.010** −0.10 0.47 0.28 0.04 *
Echocardiographic parameters of LV structure
LV Mass (mg) −0.11 0.41 −0.16 0.24 −0.11 0.41
LV AWd (mm) 0.09 0.51 −0.12 0.38 0.02 0.88
LV AWs (mm) 0.17 0.22 −0.10 0.47 0.11 0.42
LV PWd (mm) 0.24 0.08 0.17 0.21 0.23 0.09
LV PWs (mm) 0.34 0.012* 0.21 0.13 0.24 0.08
LV IDd (mm) −0.33 0.016* −0.16 0.26 −0.24 0.07
LV IDs (mm) −0.36 0.007** −0.11 0.44 −0.30 0.03 *
LV Vold (μl) −0.32 0.020* −0.16 0.24 −0.24 0.08
LV Vols (μl) −0.36 0.007** −0.11 0.44 −0.30 0.03 *
Echocardiographic parameters of LV systolic function
Ejection Fraction (%) 0.35 0.009** 0.07 0.61 0.31 0.02 *
Strainrad (%) −0.08 0.57 −0.14 0.32 0.07 0.63
Straincirc (%) −0.01 0.92 0.06 0.65 0.00 0.99
Strainlong (%) 0.12 0.40 0.08 0.58 0.14 0.31
Strainraterad (s
−1) 0.04 0.75 −0.12 0.40 0.13 0.36
Strainratecirc (s
−1) −0.17 0.22 −0.09 0.52 −0.13 0.35
Strainratelong (s
−1) −0.06 0.67 −0.08 0.59 −0.09 0.53
Echocardiographic parameters of LV diastolic function
E-wave velocity (mm/s) 0.16 0.26 −0.30 0.03 * 0.30 0.03 *
A-wave velocity (mm/s) 0.34 0.012* −0.13 0.36 0.34 0.013*
E/A −0.26 0.06 −0.01 0.95 −0.21 0.13
Pes Left ventricular end systolic pressure; Ped Left ventricular end diastolic pressure; dP/dtmax
maximal rate of pressure generation; LV Mass Left ventricular mass; LV AWx Left ventricular
anterior wall during diastole or systole respectively; LV PWx Left ventricular posterior wall
during diastole or systole respectively; LV IDx Left ventricular internal diameter during diastole
or systole respectively; LV Volx Left ventricular volume during diastole or systole respectively;
Strain Radial. circular or longitudinal strain respectively; E-wave early filling wave; A-wave
atrial filling wave; E/A early/atrial filling velocity ratio
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3.3.3.2 Correlation of ultrasound molecular imaging during T1 with
hemodynamic measurements during T2
Regression analysis for molecular imaging data during the acute phase (T1) with
the end-systolic pressure (Pes) during the chronic phase is presented in Figure 3.11.
Pes showed a negative correlation for leukocyte-targeted microbubbles (MBLc), with
higher signal predicting lower end-systolic pressure. Signals from microbubbles tar-
geted to CD4 (MBCD4) or control microbubbles (MBIso) showed a trend towards a
negative relation, but this was statistically not significant. The limited data avail-
able for P-Selectin targeted microbubbles did not show any correlation.
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Figure 3.11: Correlation of end-systolic pressure (Pes) vs. signal for (a) isotype control
microbubbles (MBIso), (b) CD4-targeted microbubbles (MBCD4), (c) P-Selectin-targeted
microbubbles (MBPSel) and (d) microbubbles targeted to activated leukocytes (MBLc).
Regression analysis with the end-diastolic pressure (Ped) during the chronic phase
is presented in Figure 3.12. Ped showed a negative correlation for leukocyte-targeted
microbubbles (MBLc) and isotype control microbubbles (MBIso). Signals from mi-
crobubbles targeted to CD4 (MBCD4) and P-Selectin (MBPSel) did not show any
correlation.
Regression analysis with the maximal rate of rise of left ventricular pressure
(dP/dTmax) during the chronic phase is presented in Figure 3.13. All microbub-
ble species did not show any correlation with dP/dTmax.
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Figure 3.12: Correlation of end-diastolic pressure (Ped) signal for (a) isotype control
microbubbles, (b) CD4-targeted microbubbles, (c) P-Selectin-targeted microbubbles and
(d) microbubbles targeted to activated leukocytes.
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Figure 3.13: Correlation of maximal rate of rise of left ventricular pressure (dP/dTmax)
signal for (a) isotype control microbubbles, (b) CD4-targeted microbubbles, (c) P-
Selectin-targeted microbubbles and (d) microbubbles targeted to activated leukocytes.
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3.3.4 Ejection fraction during the chronic phase (T2)
3.3.4.1 Correlation of functional parameters during T1 with ejection fraction
during T2
Regression analysis was performed to assess whether functional parameters acquired
during the acute phase of myocarditis (T1) are able to predict a systolic dysfunction
with a reduction in ejection fraction during the chronic phase (T2).
The results are shown in Table 3.6 on page 76.
For all parameters, only the heart rate and left ventricular mass showed a corre-
lation, with higher values being predictive for a reduction in ejection fraction.
3.3.4.2 Correlation of ultrasound molecular imaging during T1 with ejection
fraction at T2
Regression analysis was performed to assess whether molecular imaging data ac-
quired during the acute phase of myocarditis (T1) is able to predict a reduction in
ejection fraction in the chronic phase (T2) of myocarditis.
The results are shown in Table 3.5.
For the applied microbubbles there was no correlation with a change in ejection
fraction observed.
Table 3.5: Correlation analysis of ultrasound molecular imaging during the acute phase
(T1) of myocarditis with the ejection fraction during the chronic phase (T2). Data pre-
sented are nonparametric Spearman coefficients (rs) and respective two-tailed p values.
vs. Ejection Fraction (T2)
rs p-value
MBIso 0.08 0.60
MBCD4 −0.13 0.47
MBPSel −0.37 0.29
MBLc −0.11 0.45
MBIso Isotype control microbubbles; MBCD4 Microbubbles targeted against CD4; MBPSel Mi-
crobubbles targeted against P-Selectin; MBLc Microbubbles targeted against activated Leukocytes
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Table 3.6: Correlation analysis of functional parameters measured during the acute phase
(T1) of myocarditis with ejection fraction at the chronic phase (T2). Data presented are
nonparametric Spearman coefficients (rs) and respective two-tailed p values.
vs. Ejection fraction (T2)
rs p-value
Physiological parameters
Bodyweight (g) −0.08 0.57
Heart rate (bpm) −0.34 0.012*
Echocardiographic parameters of LV structure
LV Mass (mg) −0.31 0.02 *
LV AWd (mm) −0.17 0.23
LV AWs (mm) −0.03 0.83
LV PWd (mm) −0.08 0.59
LV PWs (mm) −0.07 0.60
LV IDd (mm) −0.11 0.42
LV IDs (mm) −0.18 0.19
LV Vold (μl) −0.13 0.36
LV Vols (μl) −0.18 0.19
Echocardiographic parameters of LV systolic function
Ejection Fraction (%) 0.20 0.15
Strainrad (%) −0.03 0.84
Straincirc (%) −0.03 0.85
Strainlong (%) −0.13 0.37
Strainraterad (s
−1) −0.04 0.78
Strainratecirc (s
−1) −0.02 0.90
Strainratelong (s
−1) 0.12 0.37
Echocardiographic parameters of LV diastolic function
E-wave velocity (mm/s) −0.16 0.25
A-wave velocity (mm/s) −0.27 0.05
E/A −0.02 0.88
LV Mass Left ventricular mass; LV AWx Left ventricular anterior wall during diastole respec-
tively systole; LV PWx Left ventricular posterior wall; LV IDx Left ventricular internal diameter;
LV Volx Left ventricular volume; Strain Radial. circular or longitudinal strain respectively; E-
wave early filling wave; A-wave atrial filling wave; E/A early/atrial filling velocity ratio
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3.4 Discussion
Myocarditis and the ensuing inflammatory autoimmune process can lead to chronic
dilated cardiomyopathy and heart failure. Currently available non-invasive imaging
methods detect the functional or structural consequences of infection or inflamma-
tion such as tissue necrosis or edema and are limited in diagnostic accuracy at best.
There is no diagnostic tool available to date that can predicts long-term effects
such as ventricular dilatation, development of heart failure or the need for heart
transplantation. Therefore, we examined whether contrast enhanced ultrasound
molecular imaging during the acute phase of myocarditis could be used to predict
functional impairments and structural changes in the chronic stage of myocarditis.
The main conclusion of these experiments is that ultrasound molecular imaging
during the acute phase correlates to the extent of tissue fibrosis that subsequently
develops in the chronic phase. However, this relation is weak and the clinical use-
fulness is debatable.
Changes in physiological and echocardiographic parameters
during the chronic phase of myocarditis
Physiological parameters like body weight or heart rate changed significantly be-
tween the acute phase (T1) and chronic phase (T2) of myocarditis. The age of the
animals at time point T1 and T2 was 11±1 weeks and 17±1 weeks respectively,
and thus a natural increase in body weight was expected. Comparisons with strain-
specific weight charts showed a normal increase in weight and a moderately lower
body weight for both time points. The moderate weight difference for both time
points compared to age-matched reference charts can be explained by the induced
inflammation, which causes pain and malaise as well as pathological effects on hemo-
dynamics and metabolism that myocarditis causes.
An age-dependent decrease in heart rate, as seen here in the course over six weeks,
is known in the process of aging [77]. However, the observed reduction can poten-
tially be explained by a underlying second cause. During the ongoing inflammatory
immune reaction in the myocardium, the heart rate is reported to be significantly
increased in patients suffering myocarditis [43] caused by an increased level of cir-
culating pro-inflammatory cytokines that exert a systemic effect during the acute
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phase. With a decreasing immune reaction, the heart rate will normalize eventually.
The structural parameters for anterior and posterior wall thickness are globally
decreased in the chronic phase (T2). When animals with severe myocarditis were
compared with control animals in chapter 2.3.3, especially posterior wall thicknesses
showed a marked thickening in the acute phase (T1) due to the ongoing inflam-
matory response. The subsiding of the acute inflammation leads to a volumetric
reduction of the inflamed and edematous tissue. Animals with severe myocardi-
tis will eventually progress into dilated cardiomyopathy with further decreasing LV
wall-thicknesses and widened cavity which falls in line with clinical observations in
humans [78].
The parameters of systolic function, including ejection fraction as a measure for
the amount of blood ejected out of the left ventricle and myocardial strain as a
measure of myocardial mechanics show a general decline as it would have been
expected for chronic dilated cardiomyopathy and heart failure.
The E-wave (or early ventricular filling) velocity is primarily influenced by pres-
sure gradients between left atrium – left ventricle and the rate of the ventricular
relaxation during diastole. The A-wave (or late ventricular filling) velocity on the
other hand is a measure for the velocity at atrial contraction and depends on left
atrial volume and contractile forces as well as the left ventricular chamber compli-
ance C, defined as a change of volume over pressure (C = ∆V
∆P
).
Although a significant reduction of E-wave velocities was observed in animals with
severe myocarditis compared to control animals in the acute phase, the effect is most
likely caused by a reduced ventricular relaxation. However, there was no observable
difference in E-wave velocity between time points T1 and T2.
In contrast, comparisons between time points T1 and T2 revealed a significant de-
crease in A-wave velocity which changed the E/A ratio accordingly. The ratio E/A
showed a median increase from 1.9 to 4.0, and the ratios during T1 showed a very
small variability, while the measurements during T2 spread over a much broader
range.
A reduction in A-wave velocity and thus an increased E/A ratio with unchanged
E-wave velocity could either suggest atrial dysfunction, which is associated with
dilated cardiomyopathy caused by atrial fibrosis and prevents the appropriate gen-
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eration of pressure to evacuate the atrium effectively. Or it could suggest a reduced
compliance of the left ventricle, indicating the inability of the myocardium to re-
act to the increased pressure with further sarcomer and matrix-stretching which is
usually observed in hypertrophic cardiomyopathy [79], and increased fibrotic remod-
eling where myocardial stiffening has been reported to lead to a decrease in diastolic
function [80].
Parameters that predict left ventricular fibrosis during the
chronic phase of myocarditis
The assessment of fibrosis area was performed on PicroSirius Red stained transversal
heart sections. Overall, the analyzed animals showed a median collagen-positive area
of 1% of the total stained myocardium which is comparable to findings with an aver-
age of 1% in healthy heart tissue for humans [81] and rats [82]. The collagen-rich area
is increased considerably in pathological situations as in dilated cardiomyopathies
(average of 7 %, [81]) or in myocardial infarction, where the content can vary over
a broad range and can constitute close to 100% in scar tissue [83].
Thus sixteen of the 54 analyzed animals in the cohort showed a fibrosis score greater
than 2% of total tissue area, indicating an increased collagen deposition by cardiac
fibroblasts as a consequence of cardiomyocyte damage in myocarditis.
Correlation analysis with functional parameters showed a positive relation with
heart rate during the acute phase (T1). The link between the development of fibrosis
and an increased heart rate is not well understood. There is however a well known
association of increased heart-rate with systolic heart failure and patients with di-
lated cardiomyopathy or ischemic heart diseases can show tachycardia (increased
resting heart rate) [84]. The most likely explanation is a compensatory mechanism
to counteract the decreased cardiac output for the single stroke sensed amongst
others by baroreceptors or by the action of circulating pro-inflammatory cytokines
as a systemic side effect of severe inflammation [85]. While other conditions can
contribute to an increase in heart-rate as well (e.g. pulmonary fibrosis, tachycardia
ameliorated cardiomyopathies), no screening for electrocardiographic irregularities
or pulmonary histology of the analyzed mice was performed.
The extent of fibrosis during T2 correlated with an increase of the cavity diameter
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and thus ventricular volume during the chronic stage of myocarditis (T2). However,
this was not the case for the acute phase (T1), where no structural parameter other
than the left ventricular posterior wall during diastole and LV mass had a predictive
quality.
The mechanisms behind that and the contrast to the clinical presentation with a
decrease in wall thicknesses is not well understood, but the increase in posterior
wall thickness does match the clinical observations that the posterior wall is more
frequently affected by fibrotic remodeling than the lateral or septal walls [86]. While
extensive matrix remodeling is expected at locally defined sites of damage, the my-
ocardial wall thinning is expected to occur diffusely. No other parameters during
T1, especially parameters for systolic and diastolic function did show a correlation
to the extent of tissue fibrosis during T2.
Contrast enhanced molecular ultrasound on the other hand, did show a moderate
correlation for signal from CD4-targeted microbubbles, from microbubbles targeted
to activated leukocytes and interestingly from isotype control microbubbles to the
extent of fibrosis.
Microbubbles for CD4+ cells and activated leukocytes are specific for cellular
components of the inflammatory response in myocarditis and an increased signal
during the acute phase (T1), that is caused by an increased number of attached cells
at the myocardial endothelium predicts the extent of fibrosis during the chronic
phase (T2).
Of note is the positive correlation with signal from isotype-control microbubbles.
These control microbubbles did not show attachment to CD4+ cells or CD4 protein
in vitro and in vivo experiments during the acute phase, a significant signal en-
hancement of CD4+ targeted microbubbles was shown relative to isotype-controls.
However, an increased attachment of control microbubbles to phagocytic leukocytes
on the endothelium and thus increase in signal intensity for MBIso is expected [87].
Due to the inflammatory milieu, molecular changes of the endothelium will attract
an increased number of innate phagocytic cells, which will bind pathogen-associated
molecular patterns and non-self molecules and thus increase the measured signal for
all microbubbles.
Since the signal intensity both for MBCD4 and MBLc is not significantly increased
relative to signal from MBIso, it does not allow for further deductions about the
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role of CD4+ cells or activated leukocytes in respect of the progression to dilated
cardiomyopathy.
Parameters that predict hemodynamic changes during the
chronic phase of myocarditis
Compared to published values for healthy mice, the hemodynamic changes during
the chronic phase in myocarditis reported here were an increased end-diastolic pres-
sure and the relaxation constant tau, while a reduction was found for end-systolic
pressure and the maximal rate of pressure rise and pressure decrease, respectively.
Interestingly, there was no correlation of fibrosis during the chronic stage (T2)
with a reduced capability of the heart to generate high discharge pressure at the
end of systole or with any other hemodynamic parameter during the chronic phase
(T2).
To further investigate this, all functional parameters measured at T2 were tested
against the extent of fibrosis. There was no correlation found between fibrosis and
ejection fraction, strain or strain-rate or any pressure parameters during the chronic
phase (T2). A correlation was found for heart rate, LV mass and structural param-
eters (LV volume and internal diameter). This suggests, that the extent of fibrosis
in the used model has only limited influence on both systolic and diastolic func-
tion which is surprising given the fact that myocardial fibrosis is a result of cardiac
damage during myocardial inflammation.
However, a prognostic value for a reduced end-systolic pressure was found for in-
creased LV diameters and volumes during the acute phase. Since severe myocarditis
was correlated with a reduction in LV diameter and volume because of the myocar-
dial selling during inflammation, this would indicate a potential higher end-systolic
pressure at time point T2 for animals that developed myocarditis.
This is also confirmed by heart rate, which is elevated during acute myocarditis
and is correlated as well to a higher end-systolic pressure during the chronic stage
(T2). Correlation analysis for the maximal rate of pressure rise (dP/dtmax) showed
similar relations to heart rate, LV diameter and LV volume as well as ejection frac-
tion.
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The end-diastolic pressure at the chronic stage (T2) was increased compared to
values found in the literature, but was not predicted by any of the analyzed param-
eter during the acute phase.
Signals for microbubbles showed either a trend (MBCD4) or significant correlation
(MBLc) with a reduction in LV end-systolic and maximal aortic pressures, falling in
line with the expected loss of contractile force of dilated ventricles in myocarditis.
The signals for MBLc showed a correlation with a decrease in LV end-diastolic pres-
sure as well.
hypertrophy
normal
ventricle
dilated
cardiomyopathy
V
P
V
P
V
P
LV End-Diastolic Volume
LV
 E
n
d
-D
ia
st
o
li
c 
P
re
ss
u
re
Figure 3.14: Volume-pressure
curve for hypertrophic, normal
and dilated ventricles. A higher
pressure is needed for hypertrophic
ventricles, to reach the same vol-
ume. Dilated ventricles however
offer a higher volume at the same
pressure and show a more disten-
sible ventricle. From Little et al.
[88]
Patients with dilated cardiomyopathy have
a LV end-diastolic pressure-volume relationship
that is shifted to the right. The left ventricle can
tolerate a higher volume at the same pressure
and importantly generates pressure at a lower
rate than normal ventricles [89]. A lower end-
diastolic pressure in dilated ventricles is caused
by two mechanisms.
Fist, sliding displacement of cardiomyocytes
and a decrease of wall thickness of the ventricle
[90] causes a systolic dysfunction with a decrease
of force that can be generated during systole.
Extensive matrix degradation and collagen syn-
thesis lead to a loss of fibrillar collagen, which
has an important elastic function in storing the energy generated during systole and
is released early in diastole to relax the ventricle [91]. With a decrease in systolic
pressure and a reduced spring-loaded matrix, the ventricle is impaired in its inertial
acceleration and does not develop a proper pressure-gradient or suction between
ventricle and atrium [92].
The second mechanisms is due to the cavity dilation, hemodynamic turbulences
are introduced which lead to convective deceleration of the inflowing blood [92] that
withstands the ventricular pressurization.
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Parameters that predict a decreased ejection fraction during the
chronic phase of myocarditis
A decrease in ejection fraction, which is the clinical definition of dilated cardiomy-
opathy, was observed between time points T1 and T2. Additionally, during the
chronic phase there was a very strong correlation of a decreased ejection fraction
with an increase in left ventricular diameter and volume (rs ≤-0.5; p≤0.001) clearly
indicating a progression to ventricular dilation and a reduced systolic function.
However, during the acute phase in myocarditis, only heart rate and left ventric-
ular mass showed a significant correlation with a reduced ejection fraction during
the chronic phase. No other functional parameter or finding in structural and func-
tional echocardiography during the acute phase was able to predict a reduced systolic
function during the chronic stage of myocarditis.
Ultrasound molecular imaging, which is able to detect acute inflammation dur-
ing the acute phase of myocarditis, showed no correlation to the reduced ejection
fraction in the chronic stage as well. This indicates that the progression from an
inflamed myocardium, which can be detected using ultrasound molecular imaging,
into dilated cardiomyopathy with reduction in systolic function, is not inevitable or
has other a more complex development.
The animal model, that was used and which is susceptible for the induction of
myocardial inflammation with cardiac myosin, will develop myocarditis in approxi-
mately 60% of induced animals. However, there is very little data available on the
compensatory mechanisms of the murine heart in myocarditis and the progression
to dilated cardiomyopathy. Additionally, rodents differ profoundly both in their
immune system and hemodynamic properties when compared to humans.
Limitations of this study
This study has several limitations. The used model did not allow for direct control
in the development of dilated cardiomyopathy and forced the deductive assessment
based on functional and descriptive measurements. However, patho-physiological
features have been observed that are characteristic for DCM (ejection fraction, ven-
tricular dilatation). Although it should be noted that there are significant systemic
differences in the immune system, the physical parameters (heart rate, generated
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force/mm3) and genetic distance between man and rodents [93].
Due to the spatial limitation of tissue volume that can be imaged in real-time using
molecular ultrasound imaging, the analyzed hearts cannot be characterized on a
global organ-scale, in contrast to MRI. Additionally, the limited spatial resolution
of CEU at 7MHz in the mouse model used precluded a precise regional assessment of
the disease activity. Another limitation is the routinely overestimation of LV mass
and Ejection fraction with 2D-echocardiography, compared to MRI [94] and is addi-
tionally complicated with extensive remodeling and the application in small-animal
models that exhibit a high cardiac frequency and small spatial dimensions.
Last, the average collagen content was reported to be less strict and seems to be a
less robust predictor on systolic heart-function, because small qualitative differences
in cross-linking and collagen-ratios can have a huge impact in the passive mechanical
properties [95].
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3.5 Summary
Until today, the link between myocardial inflammation in myocarditis and the de-
velopment of ventricular dilatation is not well understood because of the complexity
of the immune response and the lack of available data.
Individuals, who suffer from severe myocardial tissue damage caused by inflamma-
tory processes are at high risk to progress into dilated cardiomyopathy.
To predict the progression to dilated cardiomyopathy and subsequently heart
failure, contrast enhanced ultrasound at the acute stage of myocarditis is moderately
correlated with the extend of fibrosis as well as a reduction in end-diastolic and end-
systolic pressure.
Ejection fraction as an important parameter of systolic function during the chronic
phase in myocarditis could not be predicted with any parameters at the acute phase,
although heart rate and LV mass were correlated. However, these two parameters
are insignificant on their own in the clinical setting.
The progression into dilated cardiomyopathy is with the here applied measurements
with structural, functional and ultrasound molecular imaging not predictable in
the murine experimental autoimmune myocarditis model by relying on one single
parameter. However, the use of ultrasound molecular imaging might help one day
in diagnosing myocarditis and the progression by providing additional information
about the pathology in multi-parameter diagnostics.
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4 Conclusions
Myocarditis is defined as an inflammatory infiltration of the myocardium with my-
ocyte degeneration and necrosis in the absence of ischemia. The inflammation can
be caused by various cardiotropic pathogens or drugs. The natural course of the
disease usually is clearance of the pathogens and confinement of the inflammation.
The symptoms of the disease are often cold- or flue-like, if they are perceptible at
all. However, some patients will develop symptoms of heart failure and myocarditis
is is the main cause for sudden cardiac death in young adults.
The diagnostic tools are not satisfying, including either invasive biopsies, ex-
pensive and availability-limited magnetic resonance imaging or tests lacking either
sensitivity or specificity.
Ultrasound molecular imaging, that combines real-time imaging capabilities, a save
application and the widespread availability of ultrasound as a diagnostic tool with
molecular targeted contrast agents would be of tremendous advantage.
The aim for this study was to use contrast enhanced ultrasound (CEU) molecular
imaging to detect the inflammatory process in myocarditis at the acute stage.
In summary, the results of our study indicate that CEU molecular imaging can be
used to detect the inflammatory process in myocarditis and discriminate the disease
severity independent of cardiac function.
In addition, specific molecular imaging of a leukocyte subset that is driving the au-
toimmune process in myocarditis is possible.
As a consequence, CEU molecular imaging can potentially be useful in the diagnosis
of myocarditis at an early stage of the disease.
Patients, who have suffered severe myocardial tissue damage caused by the in-
flammatory processes during the acute phase are at risk to progress into dilated
86
cardiomyopathy (DCM) and subsequently heart failure.
To date, there is no diagnostic tool available that offers robust prognostic infor-
mation during the inflammatory process that can predict the extent of the cardiac
remodeling and development of DCM.
To predict the progression to dilated cardiomyopathy and subsequently heart fail-
ure, contrast enhanced ultrasound at the acute stage of myocarditis was performed.
The results for molecular imaging during the acute phase is moderately correlated
with the extend of fibrosis as well as a reduction in end-diastolic and end-systolic
pressure at the chronic phase of myocarditis.
Ejection fraction as an important parameter of systolic function during the chronic
phase could not be predicted with any parameters at the acute phase, although heart
rate and LV mass were correlated. However, these two parameters are insignificant
on their own in the clinical setting.
The progression into dilated cardiomyopathy is with the here applied measurements
with structural, functional and ultrasound molecular imaging not predictable in the
murine experimental autoimmune myocarditis model by relying on one single pa-
rameter.
However, the use of ultrasound molecular imaging might help one day in diagnos-
ing myocarditis and the progression by providing additional information about the
pathology in multi-parameter diagnostics.
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